VAN ANDEL RESEARCH INSTITUTE
Cite this
Plain text VAN ANDEL RESEARCH INSTITUTE. furp.org, nonprofit organization profile, tax years 2009–2023. https://furp.org/org/van-andel-research-institute-522000823. Retrieved 2026-10-25.
APA furp.org. (n.d.). VAN ANDEL RESEARCH INSTITUTE [Nonprofit organization profile; tax years 2009–2023]. Retrieved October 25, 2026, from https://furp.org/org/van-andel-research-institute-522000823
MLA “VAN ANDEL RESEARCH INSTITUTE.” furp.org, tax years 2009–2023, https://furp.org/org/van-andel-research-institute-522000823. Accessed 25 Oct. 2026.
Retrieved 2026-10-25; covers tax years 2009–2023. Data: furp.org, CC BY 4.0.
2023 · Form 990 · revenue $112.7M · expenses $118.9M · assets $190.5M
- EIN
- 52-2000823
- Address
- 333 BOSTWICK AVE NE, GRAND RAPIDS, MI 49503-2518
- Website
- WWW.VAI.ORG
- NTEE code
- H300
- Exempt type
- 501(c)(3): charitable, religious, educational, scientific or literary (trust)
- Ruling date
- July 1997 (when the IRS recognized its exemption)
- IRS status
- Exempt (unconditional) (IRS Business Master File) IRS data ↗
- Tax-deductible donations
- Yes: listed in IRS Publication 78 (public charity) Pub 78 ↗
- Foundation status
- Hospital or medical research organization
- Cross-check
- ProPublica Nonprofit Explorer
Mission
MEDICAL RESEARCH ORGANIZATION VAN ANDEL RESEARCH INSTITUTE IS AN INDEPENDENT BIOMEDICAL RESEARCH ORGANIZATION COMMITTED TO IMPROVING THE HEALTH AND ENHANCING THE LIVES OF CURRENT AND FUTURE GENERATIONS.
Each tax year counts once: when a return was amended, only the latest return for that period is used below (superseded returns stay listed, greyed, under Finances).
People paid by the organization
48 people paid across every filing: current people first, then by total pay from this organization. Organizations counts every nonprofit each person appears on.
| Name | Latest title | Years | Latest year pay | Total pay from here | Organizations |
|---|---|---|---|---|---|
| Kathy Vogelsang | CHIEF INVESTMENT OFFICER | 2014-2023 | $1,722,571 | $11,041,459 | 1 |
| David Van Andel | CHAIRMAN / CEO | 2009-2023 | $799,595 | $8,982,210 | 5 |
| Dr Peter Jones | CHIEF SCIENTIFIC OFFICER & RES. DIR. | 2015-2023 | $1,118,685 | $8,840,606 | 2 |
| Dr Jana Hall | CHIEF OPERAT. OFFICER (END 4/1/2024) | 2011-2023 | $736,893 | $6,439,152 | 3 |
| Ted Heilman | ASSOC DIRECT-SR. PORTFOLIO MGR. | 2009-2023 | $1,240,706 | $6,043,061 | 1 |
| Timothy Myers | VICE PRESIDENT & CAO/CFO | 2009-2023 | $586,322 | $5,771,025 | 5 |
| Dr Peter Laird | DISTINGUISHED INVESTIGATOR | 2015-2023 | $576,490 | $4,582,711 | 1 |
| Gerald Callahan | CHIEF STRAT. OFFICER (END 7/5/2024) | 2013-2023 | $603,299 | $4,454,279 | 3 |
| Thomas Curran Jr | GENERAL COUNSEL | 2019-2023 | $612,973 | $2,588,031 | 4 |
| Austin Way | SENIOR PORTFOLIO MANAGER | 2022-2023 | $843,838 | $1,555,659 | 1 |
| Dr Huilin Li | SR. SCIENTIFIC INVESTIGATOR & DEPT. CHAIR | 2023 | $506,125 | $506,125 | 1 |
| Dr James Fahner | TRUSTEE | 2009-2023 | $11,750 | $171,450 | 2 |
| Dr Max Wicha | TRUSTEE | 2015-2023 | $10,500 | $92,000 | 1 |
| Dr Michelle Lebeau | TRUSTEE | 2015-2023 | $9,500 | $68,000 | 1 |
| Dr Ralph Deberardinis | TRUSTEE | 2022-2023 | $7,500 | $9,500 | 1 |
| Dr Patrik Brundin (former) | ASSOCIATE RESEARCH DIRECTOR | 2012-2021 | $687,303 | $5,987,425 | 1 |
| Dr George Vande Woude (former) | TRUSTEE (ENDED 4/13/2021) | 2009-2020 | $6,000 | $3,029,160 | 1 |
| David Whitescarver (former) | FORMER SECRETARY/V.P. | 2010-2017 | $295,363 | $2,791,618 | 1 |
| Dr Gerd Pfeifer (former) | SR. SCIENTIFIC INVESTIGATOR | 2015-2022 | $507,008 | $2,587,368 | 1 |
| Dr Scott Jewell (former) | DIRECTOR OF CORES | 2011-2020 | $466,768 | $2,473,154 | 1 |
| Dr H Eric Xu (former) | INVESTIGATOR | 2009-2014 | $359,650 | $1,928,288 | 1 |
| Jeffrey M Trent Phd (former) | PRESIDENT & RESEARCH DIREC | 2009-2010 | $1,346,435 | $1,435,068 | 4 |
| Dr Jeffrey Trentthrough 312 (former) | PRESIDENT & RESEARCH DIRECTOR | 2011 | $1,424,679 | $1,424,679 | 1 |
| Love Collins Iii (former) | V.P. OF DEVELOPMENT, COMM. & MKTNG. | 2012-2013 | $382,294 | $736,370 | 1 |
| Dr Jeffrey Trent Done 312 (former) | PRESIDENT & RESEARCH DIRECTOR | 2012 | $708,111 | $708,111 | 1 |
| R Jack Frick (former) | CHIEF ADMINISTRATIVE OFFICER | 2009-2010 | $366,684 | $686,174 | 1 |
| Bryon Campbell (former) | CHIEF INFORMATION OFFICER | 2009-2011 | $227,074 | $643,271 | 1 |
| Steve Heacock Former (former) | CAO / GENERAL COUNSEL | 2010 | $638,214 | $638,214 | 1 |
| Dr Peter Jones Start 21714 (former) | CHIEF SCIENTIFIC OFFICER & RES. DIR. | 2014 | $626,502 | $626,502 | 1 |
| John Bender (former) | CLINICAL OPERATIONS DIRECTOR | 2009-2011 | $285,081 | $549,924 | 2 |
| Kathleen Vogelsang (former) | DIR OF INVESTMENTS | 2009-2010 | $216,313 | $487,928 | 1 |
| Dr James Resau (former) | DIST INVESTIGATOR | 2009-2010 | $232,410 | $436,663 | 1 |
| R Jack Frick Through 1211 (former) | CHIEF ADMINISTRATIVE OFFICER | 2011 | $371,227 | $371,227 | 1 |
| Steve Heacock (former) | CAO / GENERAL COUNSEL | 2009 | $363,795 | $363,795 | 1 |
| John Bender Done 513 (former) | CLINICAL OPERATIONS DIRECTOR | 2012 | $299,238 | $299,238 | 1 |
| Dr Giselle Sholler Done 613 (former) | INVESTIGATOR | 2012 | $292,185 | $292,185 | 1 |
| R Jack Frick Done 1211 (former) | CHIEF ADMINISTRATIVE OFFICER | 2012 | $273,377 | $273,377 | 1 |
| Dr Giselle Saulnier Sholler (former) | DIST INVESTIGATOR | 2011 | $257,660 | $257,660 | 1 |
| Joseph Gavan (former) | VP-Communications & Development | 2009 | $219,723 | $219,723 | 1 |
| R Jack Frick Done 121111 (former) | CHIEF ADMINISTRATIVE OFFICER -FORMER | 2013 | $187,705 | $187,705 | 1 |
| Linda Zarzecki (former) | VICE PRESIDENT OF HUMAN RESOURCES | 2009 | $162,754 | $162,754 | 1 |
| Dr Tom Demeester (former) | TRUSTEE (END 12/12/2022) | 2015-2022 | $8,000 | $59,500 | 1 |
| Dr Ralph Weichselbaum (former) | TRUSTEE (ENDED 09/10/18) | 2012-2017 | $9,000 | $39,500 | 1 |
| Dr Fritz Rottman Phd (former) | TRUSTEE | 2009-2011 | $12,000 | $39,000 | 1 |
| Dr Gary Tarpley (former) | TRUSTEE | 2011-2013 | $10,000 | $22,500 | 1 |
| Dr Gary Tarpley Done 10715 (former) | TRUSTEE | 2014 | $10,000 | $10,000 | 1 |
| Jose Cardenas (former) | TRUSTEE | 2009-2010 | $10,000 | $10,000 | 3 |
| William Post Through 312 (former) | TRUSTEE | 2011 | $2,000 | $2,000 | 1 |
Officers and directors, no compensation reported
3 people listed on the returns with $0 (or no amount) in every compensation column: current people first. Hours are as filed on the latest return each person appears on.
| Name | Latest title | Years | Hrs/wk (latest) | Compensation | Organizations |
|---|---|---|---|---|---|
| Dr Henry Paulson | TRUSTEE (BEG. 9/23/2024) | 2023 | 1 | $0 reported | 1 |
| William Post (former) | TRUSTEE | 2010 | 1 | $0 reported | 1 |
| Jeffrey Battershall (former) | SECRETARY/ INTERIM CHIEF LEGAL | 2009-2010 | 1 | $0 reported | 1 |
People by year
2023 · 16 people listed · 15 paid, $9.4M · 596 employees · 0 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| KATHY VOGELSANG | CHIEF INVESTMENT OFFICER | 45 | $1,125,167 | $0 | $597,404 | $1,722,571 | 1 |
| TED HEILMAN | ASSOC DIRECT-SR. PORTFOLIO MGR. | 45 | $782,302 | $0 | $458,404 | $1,240,706 | 1 |
| DR PETER JONES | CHIEF SCIENTIFIC OFFICER & RES. DIR. | 44 | $953,170 | $0 | $165,515 | $1,118,685 | 2 |
| AUSTIN WAY | SENIOR PORTFOLIO MANAGER | 45 | $530,219 | $0 | $313,619 | $843,838 | 1 |
| DAVID VAN ANDEL | CHAIRMAN / CEO | 23 | $691,507 | $0 | $108,088 | $799,595 | 5 |
| DR JANA HALL | CHIEF OPERAT. OFFICER (END 4/1/2024) | 44 | $635,819 | $0 | $101,074 | $736,893 | 3 |
| THOMAS CURRAN JR | GENERAL COUNSEL | 42 | $517,831 | $0 | $95,142 | $612,973 | 4 |
| GERALD CALLAHAN | CHIEF STRAT. OFFICER (END 7/5/2024) | 43 | $508,121 | $0 | $95,178 | $603,299 | 3 |
| TIMOTHY MYERS | VICE PRESIDENT & CAO/CFO | 42 | $492,899 | $0 | $93,423 | $586,322 | 5 |
| DR PETER LAIRD | DISTINGUISHED INVESTIGATOR | 45 | $513,955 | $0 | $62,535 | $576,490 | 1 |
| DR HUILIN LI | SR. SCIENTIFIC INVESTIGATOR & DEPT. CHAIR | 45 | $433,939 | $0 | $72,186 | $506,125 | 1 |
| DR JAMES FAHNER | TRUSTEE | 1 | $7,000 | $4,750 | $0 | $11,750 | 2 |
| DR MAX WICHA | TRUSTEE | 1 | $9,500 | $1,000 | $0 | $10,500 | 1 |
| DR MICHELLE LEBEAU | TRUSTEE | 1 | $9,500 | $0 | $0 | $9,500 | 1 |
| DR RALPH DEBERARDINIS | TRUSTEE | 1 | $7,500 | $0 | $0 | $7,500 | 1 |
| DR HENRY PAULSON | TRUSTEE (BEG. 9/23/2024) | 1 | $0 | $0 | $0 | $0 | 1 |
2022 · 16 people listed · 16 paid, $9.2M · 554 employees · 0 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| KATHY VOGELSANG | CHIEF INVESTMENT OFFICER | 45 | $1,100,527 | $0 | $484,712 | $1,585,239 | 1 |
| DR PETER JONES | CHIEF SCIENTIFIC OFFICER & RES. DIR. | 44 | $909,200 | $0 | $313,089 | $1,222,289 | 2 |
| TED HEILMAN | ASSOC DIRECT-SR. PORTFOLIO MGR. | 45 | $707,489 | $0 | $374,712 | $1,082,201 | 1 |
| DAVID VAN ANDEL | CHAIRMAN / CEO | 23 | $621,229 | $0 | $230,734 | $851,963 | 5 |
| DR JANA HALL | CHIEF OPERATIONS OFFICER | 44 | $570,615 | $0 | $199,977 | $770,592 | 3 |
| AUSTIN WAY | SENIOR PORTFOLIO MANAGER | 45 | $454,273 | $0 | $257,548 | $711,821 | 1 |
| GERALD CALLAHAN | CHIEF STRATEGIC OFFICER | 43 | $470,651 | $0 | $158,502 | $629,153 | 3 |
| THOMAS CURRAN JR | GENERAL COUNSEL | 42 | $477,531 | $0 | $145,590 | $623,121 | 4 |
| DR PETER LAIRD | DISTINGUISHED INVESTIGATOR | 45 | $490,598 | $0 | $101,690 | $592,288 | 1 |
| TIMOTHY MYERS | V.P. & CHIEF FINANCIAL OFFICER | 42 | $429,420 | $0 | $141,837 | $571,257 | 5 |
| DR GERD PFEIFER | SR. SCIENTIFIC INVESTIGATOR | 45 | $438,778 | $0 | $68,230 | $507,008 | 1 |
| DR MAX WICHA | TRUSTEE | 1 | $14,000 | $0 | $0 | $14,000 | 1 |
| DR JAMES FAHNER | TRUSTEE | 1 | $9,500 | $2,000 | $0 | $11,500 | 2 |
| DR MICHELLE LEBEAU | TRUSTEE | 1 | $9,000 | $0 | $0 | $9,000 | 1 |
| DR TOM DEMEESTER | TRUSTEE (END 12/12/2022) | 1 | $8,000 | $0 | $0 | $8,000 | 1 |
| DR RALPH DEBERARDINIS | TRUSTEE (BEG. 11/20/2023) | 1 | $2,000 | $0 | $0 | $2,000 | 1 |
2021 · 15 people listed · 15 paid, $7.7M · 507 employees · 10 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| KATHY VOGELSANG | CHIEF INVESTMENT OFFICER | 45 | $777,007 | $0 | $577,827 | $1,354,834 | 1 |
| DR PETER JONES | CHIEF SCIENTIFIC OFFICER & RES. DIR. | 44 | $742,491 | $0 | $227,966 | $970,457 | 2 |
| TED HEILMAN | ASSOC DIRECT-SR. PORTFOLIO MGR. | 45 | $458,222 | $0 | $388,710 | $846,932 | 1 |
| DR PATRIK BRUNDIN | ASSOCIATE RESEARCH DIRECTOR | 45 | $536,387 | $0 | $150,916 | $687,303 | 1 |
| DAVID VAN ANDEL | CHAIRMAN / CEO | 23 | $460,906 | $0 | $174,139 | $635,045 | 5 |
| DR JANA HALL | CHIEF OPERATIONS OFFICER | 44 | $471,244 | $0 | $157,678 | $628,922 | 3 |
| DR PETER LAIRD | DISTINGUISHED INVESTIGATOR | 45 | $468,855 | $0 | $89,135 | $557,990 | 1 |
| GERALD CALLAHAN | CHIEF STRATEGIC OFFICER | 43 | $404,818 | $0 | $128,718 | $533,536 | 3 |
| THOMAS CURRAN JR | GENERAL COUNSEL | 42 | $407,171 | $0 | $114,355 | $521,526 | 4 |
| DR GERD PFEIFER | SR. SCIENTIFIC INVESTIGATOR | 45 | $405,667 | $0 | $56,911 | $462,578 | 1 |
| TIMOTHY MYERS | V.P. & CHIEF FINANCIAL OFFICER | 42 | $353,328 | $0 | $104,995 | $458,323 | 5 |
| DR JAMES FAHNER | TRUSTEE | 1 | $9,000 | $2,000 | $0 | $11,000 | 2 |
| DR MAX WICHA | TRUSTEE | 1 | $9,000 | $0 | $0 | $9,000 | 1 |
| DR MICHELLE LEBEAU | TRUSTEE | 1 | $9,000 | $0 | $0 | $9,000 | 1 |
| DR TOM DEMEESTER | TRUSTEE | 1 | $9,000 | $0 | $0 | $9,000 | 1 |
2020 · 16 people listed · 16 paid, $7.0M · 525 employees · 10 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| KATHY VOGELSANG | CHIEF INVESTMENT OFFICER | 45 | $917,544 | $0 | $281,127 | $1,198,671 | 1 |
| DR PETER JONES | CHIEF SCIENTIFIC OFFICER & RES. DIR. | 52 | $837,546 | $0 | $111,970 | $949,516 | 2 |
| TED HEILMAN | ASSOC DIRECT-SR. PORTFOLIO MGR. | 45 | $511,979 | $0 | $180,699 | $692,678 | 1 |
| DR PATRIK BRUNDIN | ASSOCIATE RESEARCH DIRECTOR | 45 | $571,604 | $0 | $76,109 | $647,713 | 1 |
| DR JANA HALL | CHIEF OPERATIONS OFFICER | 52 | $530,961 | $0 | $63,562 | $594,523 | 3 |
| DR PETER LAIRD | DISTINGUISHED INVESTIGATOR | 45 | $460,314 | $0 | $72,000 | $532,314 | 1 |
| GERALD CALLAHAN | CHIEF STRATEGIC OFFICER | 51 | $447,678 | $0 | $70,720 | $518,398 | 3 |
| THOMAS CURRAN JR | GENERAL COUNSEL | 50 | $402,445 | $0 | $70,627 | $473,072 | 4 |
| DAVID VAN ANDEL | CHAIRMAN / CEO | 36 | $433,141 | $0 | $35,955 | $469,096 | 5 |
| DR SCOTT JEWELL | DIRECTOR OF CORES | 45 | $414,976 | $0 | $51,792 | $466,768 | 1 |
| TIMOTHY MYERS | V.P. & CHIEF FINANCIAL OFFICER | 50 | $374,610 | $0 | $66,577 | $441,187 | 5 |
| DR MAX WICHA | TRUSTEE | 1 | $15,000 | $0 | $0 | $15,000 | 1 |
| DR JAMES FAHNER | TRUSTEE | 1 | $9,000 | $2,000 | $0 | $11,000 | 2 |
| DR MICHELLE LEBEAU | TRUSTEE | 1 | $9,000 | $0 | $0 | $9,000 | 1 |
| DR TOM DEMEESTER | TRUSTEE | 1 | $9,000 | $0 | $0 | $9,000 | 1 |
| DR GEORGE VANDE WOUDE | TRUSTEE (ENDED 4/13/2021) | 1 | $6,000 | $0 | $0 | $6,000 | 1 |
2019 · 16 people listed · 16 paid, $7.1M · 525 employees · 12 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| KATHY VOGELSANG | CHIEF INVESTMENT OFFICER | 45 | $742,294 | $0 | $438,840 | $1,181,134 | 1 |
| DR PETER JONES | CHIEF SCIENTIFIC OFFICER & RES. DIR. | 52 | $752,533 | $0 | $235,728 | $988,261 | 2 |
| TED HEILMAN | ASSOC DIRECT-SR. PORTFOLIO MGR. | 45 | $418,301 | $0 | $262,994 | $681,295 | 1 |
| DAVID VAN ANDEL | CHAIRMAN / CEO | 36 | $520,256 | $0 | $156,846 | $677,102 | 5 |
| DR PATRIK BRUNDIN | ASSOCIATE RESEARCH DIRECTOR | 45 | $529,770 | $0 | $117,375 | $647,145 | 1 |
| DR JANA HALL | CHIEF OPERATIONS OFFICER | 52 | $463,709 | $0 | $145,389 | $609,098 | 3 |
| GERALD CALLAHAN | CHIEF STRATEGIC OFFICER | 51 | $381,738 | $0 | $125,592 | $507,330 | 3 |
| DR PETER LAIRD | DISTINGUISHED INVESTIGATOR | 45 | $431,975 | $0 | $74,632 | $506,607 | 1 |
| TIMOTHY MYERS | V.P. & CHIEF FINANCIAL OFFICER | 50 | $344,197 | $0 | $99,590 | $443,787 | 5 |
| DR GERD PFEIFER | SR. SCIENTIFIC INVESTIGATOR | 45 | $384,927 | $0 | $47,603 | $432,530 | 1 |
| THOMAS CURRAN JR | GENERAL COUNSEL | 50 | $276,743 | $0 | $80,596 | $357,339 | 4 |
| DR MAX WICHA | TRUSTEE | 1 | $13,000 | $0 | $0 | $13,000 | 1 |
| DR JAMES FAHNER | TRUSTEE | 1 | $7,000 | $2,200 | $0 | $9,200 | 2 |
| DR GEORGE VANDE WOUDE | TRUSTEE | 1 | $9,000 | $0 | $0 | $9,000 | 1 |
| DR TOM DEMEESTER | TRUSTEE | 1 | $9,000 | $0 | $0 | $9,000 | 1 |
| DR MICHELLE LEBEAU | TRUSTEE | 1 | $8,000 | $0 | $0 | $8,000 | 1 |
2018 · 14 people listed · 14 paid, $5.8M · 479 employees · 16 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| KATHY VOGELSANG | CHIEF INVESTMENT OFFICER | 45 | $769,994 | $0 | $288,450 | $1,058,444 | 1 |
| DR PETER JONES | CHIEF SCIENTIFIC OFFICER & RES. DIR. | 52 | $736,084 | $0 | $168,951 | $905,035 | 2 |
| TED HEILMAN | ASSOC DIRECT-SR. PORTFOLIO MGR. | 45 | $453,788 | $0 | $179,418 | $633,206 | 1 |
| DAVID VAN ANDEL | CHAIRMAN / CEO | 36 | $510,007 | $0 | $112,315 | $622,322 | 5 |
| DR PATRIK BRUNDIN | ASSOCIATE RESEARCH DIRECTOR | 45 | $513,904 | $0 | $87,587 | $601,491 | 1 |
| DR JANA HALL | CHIEF OPERATIONS OFFICER | 52 | $457,885 | $0 | $110,728 | $568,613 | 3 |
| DR PETER LAIRD | INVESTIGATOR | 45 | $410,026 | $0 | $55,027 | $465,053 | 1 |
| DR SCOTT JEWELL | DIR. PROGRAM FOR TECHNOLOGIES & CORES | 53 | $376,114 | $0 | $79,166 | $455,280 | 1 |
| TIMOTHY MYERS | V.P. & CHIEF FINANCIAL OFFICER | 50 | $334,088 | $0 | $85,549 | $419,637 | 5 |
| DR JAMES FAHNER | TRUSTEE | 1 | $8,000 | $3,000 | $0 | $11,000 | 2 |
| DR GEORGE VANDE WOUDE | TRUSTEE | 1 | $8,000 | $0 | $0 | $8,000 | 1 |
| DR MAX WICHA | TRUSTEE | 1 | $8,000 | $0 | $0 | $8,000 | 1 |
| DR TOM DEMEESTER | TRUSTEE | 1 | $8,000 | $0 | $0 | $8,000 | 1 |
| DR MICHELLE LEBEAU | TRUSTEE | 1 | $7,000 | $0 | $0 | $7,000 | 1 |
2017 · 16 people listed · 16 paid, $6.3M · 449 employees · 16 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| KATHY VOGELSANG | CHIEF INVESTMENT OFFICER | 45 | $610,494 | $0 | $371,506 | $982,000 | 1 |
| DR PETER JONES | CHIEF SCIENTIFIC OFFICER & RES. DIR. | 52 | $712,053 | $0 | $202,298 | $914,351 | 2 |
| TED HEILMAN | ASSOC DIRECT-SR. PORTFOLIO MGR. | 45 | $406,010 | $0 | $229,054 | $635,064 | 1 |
| DAVID VAN ANDEL | CHAIRMAN / CEO | 36 | $490,327 | $0 | $129,226 | $619,553 | 5 |
| DR PATRIK BRUNDIN | ASSOCIATE RESEARCH DIRECTOR | 45 | $488,766 | $0 | $115,385 | $604,151 | 1 |
| DR JANA HALL | CHIEF OPERATIONS OFFICER | 50 | $423,365 | $0 | $147,856 | $571,221 | 3 |
| DR PETER LAIRD | INVESTIGATOR | 45 | $403,258 | $0 | $58,817 | $462,075 | 1 |
| TIMOTHY MYERS | V.P. & CHIEF FINANCIAL OFFICER | 50 | $308,792 | $0 | $107,081 | $415,873 | 5 |
| DR GERD PFEIFER | INVESTIGATOR | 45 | $360,876 | $0 | $46,218 | $407,094 | 1 |
| DR GEORGE VANDE WOUDE | TRUSTEE/INVESTIGATOR | 0 | $269,298 | $0 | $28,352 | $297,650 | 1 |
| DAVID WHITESCARVER | FORMER SECRETARY/V.P. | 0 | $295,363 | $0 | $0 | $295,363 | 1 |
| DR MAX WICHA | TRUSTEE | 1 | $13,000 | $0 | $0 | $13,000 | 1 |
| DR JAMES FAHNER | TRUSTEE | 1 | $10,000 | $2,000 | $0 | $12,000 | 2 |
| DR MICHELLE LEBEAU | TRUSTEE | 1 | $10,000 | $0 | $0 | $10,000 | 1 |
| DR TOM DEMEESTER | TRUSTEE | 1 | $10,000 | $0 | $0 | $10,000 | 1 |
| DR RALPH WEICHSELBAUM | TRUSTEE (ENDED 09/10/18) | 1 | $9,000 | $0 | $0 | $9,000 | 1 |
2016 · 16 people listed · 16 paid, $5.8M · 449 employees · 17 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| DR PETER JONES | CHIEF SCIENTIFIC OFFICER & RES. DIR. | 53 | $703,892 | $0 | $187,623 | $891,515 | 2 |
| KATHY VOGELSANG | CHIEF INVESTMENT OFFICER | 45 | $431,378 | $0 | $285,963 | $717,341 | 1 |
| DR PATRIK BRUNDIN | ASSOCIATE RESEARCH DIRECTOR | 45 | $476,236 | $0 | $101,475 | $577,711 | 1 |
| DAVID VAN ANDEL | CHAIRMAN / CEO | 36 | $442,120 | $0 | $129,404 | $571,524 | 5 |
| DR JANA HALL | CHIEF OPERATIONS OFFICER | 52 | $394,557 | $0 | $118,663 | $513,220 | 3 |
| DR PETER LAIRD | INVESTIGATOR | 45 | $393,922 | $0 | $60,411 | $454,333 | 1 |
| DR GERALD CALLAHAN | V.P., INNOVATIONS & COLLABORATIONS | 45 | $349,955 | $0 | $103,683 | $453,638 | 3 |
| DAVID WHITESCARVER | FORMER SECRETARY/V.P.(ENDED 8/31/16) | 0 | $367,546 | $0 | $61,794 | $429,340 | 1 |
| DR GERD PFEIFER | INVESTIGATOR | 45 | $347,966 | $0 | $47,795 | $395,761 | 1 |
| TIMOTHY MYERS | V.P. & CHIEF FINANCIAL OFFICER | 50 | $298,609 | $0 | $85,683 | $384,292 | 5 |
| DR GEORGE VANDE WOUDE | TRUSTEE/INVESTIGATOR (ENDED 9/30/17) | 45 | $302,486 | $0 | $28,328 | $330,814 | 1 |
| DR JAMES FAHNER | TRUSTEE | 1 | $10,000 | $2,000 | $0 | $12,000 | 2 |
| DR RALPH WEICHSELBAUM | TRUSTEE | 1 | $9,000 | $0 | $0 | $9,000 | 1 |
| DR MICHELLE LEBEAU | TRUSTEE | 1 | $6,500 | $0 | $0 | $6,500 | 1 |
| DR TOM DEMEESTER | TRUSTEE | 1 | $6,500 | $0 | $0 | $6,500 | 1 |
| DR MAX WICHA | TRUSTEE | 1 | $4,500 | $0 | $0 | $4,500 | 1 |
2015 · 16 people listed · 14 paid, $5.6M · 424 employees · 0 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| DR PETER JONES | CHIEF SCIENTIFIC OFFICER & RES. DIR. | 53 | $718,385 | $0 | $162,112 | $880,497 | 2 |
| KATHY VOGELSANG | CHIEF INVESTMENT OFFICER | 45 | $448,562 | $0 | $166,450 | $615,012 | 1 |
| DR PATRIK BRUNDIN | VARI ASSOCIATE DIRECTOR OF RESEARCH | 45 | $496,115 | $0 | $81,487 | $577,602 | 1 |
| DAVID VAN ANDEL | CHAIRMAN / CEO | 36 | $460,118 | $0 | $97,010 | $557,128 | 5 |
| DR JANA HALL | CHIEF OPERATIONS OFFICER | 52 | $376,331 | $0 | $88,423 | $464,754 | 3 |
| DR GERALD CALLAHAN | V.P., INNOVATIONS & COLLABORATIONS | 45 | $353,343 | $0 | $108,630 | $461,973 | 3 |
| DAVID WHITESCARVER | SECRETARY/V.P. & CHIEF LEGAL OFFICER | 50 | $368,119 | $0 | $93,443 | $461,562 | 1 |
| DR PETER LAIRD | INVESTIGATOR | 45 | $380,163 | $0 | $55,398 | $435,561 | 1 |
| DR GERD PFEIFER | INVESTIGATOR | 45 | $345,252 | $0 | $37,145 | $382,397 | 1 |
| TIMOTHY MYERS | V.P. & CHIEF FINANCIAL OFFICER | 50 | $296,165 | $0 | $78,374 | $374,539 | 5 |
| DR GEORGE VANDE WOUDE | TRUSTEE/ INVESTIGATOR | 45 | $314,025 | $0 | $22,903 | $336,928 | 1 |
| DR JAMES FAHNER | TRUSTEE | 1 | $10,000 | $2,000 | $0 | $12,000 | 2 |
| DR RALPH WEICHSELBAUM | TRUSTEE | 1 | $8,000 | $0 | $0 | $8,000 | 1 |
| DR MAX WICHA | TRUSTEE | 1 | $5,000 | $0 | $0 | $5,000 | 1 |
| DR MICHELLE LEBEAU | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| DR TOM DEMEESTER | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
2014 · 14 people listed · 14 paid, $5.3M · 399 employees · 0 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| DR PETER JONES START 21714 | CHIEF SCIENTIFIC OFFICER & RES. DIR. | 53 | $432,331 | $0 | $194,171 | $626,502 | 1 |
| KATHY VOGELSANG | CHIEF INVESTMENT OFFICER | 45 | $410,046 | $0 | $216,167 | $626,213 | 1 |
| DR PATRIK BRUNDIN | VARI ASSOCIATE DIRECTOR OF RESEARCH | 45 | $502,889 | $0 | $99,267 | $602,156 | 1 |
| DAVID VAN ANDEL | CHAIRMAN / CEO | 36 | $445,515 | $0 | $136,845 | $582,360 | 5 |
| DAVID WHITESCARVER | SECRETARY/V.P. & CHIEF LEGAL OFFICER | 50 | $372,187 | $0 | $105,189 | $477,376 | 1 |
| DR JANA HALL | CHIEF OPERATIONS OFFICER | 50 | $354,023 | $0 | $106,110 | $460,133 | 3 |
| DR GERALD CALLAHAN | V.P., INNOVATIONS & COLLABORATIONS | 45 | $311,438 | $0 | $118,810 | $430,248 | 3 |
| DR SCOTT JEWELL | INVESTIGATOR | 45 | $354,571 | $0 | $60,446 | $415,017 | 1 |
| DR H ERIC XU | INVESTIGATOR | 45 | $308,932 | $0 | $50,718 | $359,650 | 1 |
| TIMOTHY MYERS | V.P. & CHIEF FINANCIAL OFFICER | 50 | $256,638 | $0 | $83,296 | $339,934 | 5 |
| DR GEORGE VANDE WOUDE | TRUSTEE/ INVESTIGATOR | 45 | $302,486 | $0 | $27,326 | $329,812 | 1 |
| DR JAMES FAHNER | TRUSTEE | 1 | $10,000 | $2,000 | $0 | $12,000 | 2 |
| DR GARY TARPLEY DONE 10715 | TRUSTEE | 1 | $10,000 | $0 | $0 | $10,000 | 1 |
| DR RALPH WEICHSELBAUM | TRUSTEE | 1 | $9,000 | $0 | $0 | $9,000 | 1 |
2013 · 14 people listed · 14 paid, $4.3M · 402 employees · 0 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| DR PATRIK BRUNDIN | VARI ASSOCIATE DIRECTOR OF RESEARCH | 45 | $475,233 | $0 | $112,798 | $588,031 | 1 |
| DAVID VAN ANDEL | CHAIRMAN / CEO | 36 | $416,751 | $0 | $133,745 | $550,496 | 5 |
| DAVID WHITESCARVER | SECRETARY/V.P. & CHIEF LEGAL OFFICER | 50 | $356,220 | $0 | $128,674 | $484,894 | 1 |
| DR JANA HALL | CHIEF OPERATIONS OFFICER | 50 | $316,987 | $0 | $99,279 | $416,266 | 3 |
| DR SCOTT JEWELL | INVESTIGATOR | 45 | $317,294 | $0 | $66,139 | $383,433 | 1 |
| LOVE COLLINS III | V.P. OF DEVELOPMENT, COMM. & MKTNG. | 45 | $292,750 | $0 | $89,544 | $382,294 | 1 |
| DR H ERIC XU | INVESTIGATOR | 45 | $296,596 | $0 | $53,125 | $349,721 | 1 |
| DR GEORGE VANDE WOUDE | TRUSTEE/ INVESTIGATOR | 50 | $300,227 | $0 | $26,792 | $327,019 | 1 |
| GERALD CALLAHAN | V.P. OF BUSINESS DEVELOPMENT | 45 | $231,554 | $0 | $85,150 | $316,704 | 3 |
| TIMOTHY MYERS | V.P. & CHIEF FINANCIAL OFFICER | 50 | $235,524 | $0 | $79,088 | $314,612 | 5 |
| R JACK FRICK DONE 121111 | CHIEF ADMINISTRATIVE OFFICER -FORMER | 0 | $187,705 | $0 | $0 | $187,705 | 1 |
| DR JAMES FAHNER | TRUSTEE | 1 | $10,000 | $2,000 | $0 | $12,000 | 2 |
| DR GARY TARPLEY | TRUSTEE | 1 | $10,000 | $0 | $0 | $10,000 | 1 |
| DR RALPH WEICHSELBAUM | TRUSTEE | 1 | $4,500 | $0 | $0 | $4,500 | 1 |
2012 · 16 people listed · 15 paid, $4.8M · 393 employees · 0 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| DR JEFFREY TRENT DONE 312 | PRESIDENT & RESEARCH DIRECTOR | 0 | $702,479 | $0 | $5,632 | $708,111 | 1 |
| DAVID VAN ANDEL | CHAIRMAN / CEO | 36 | $405,693 | $0 | $110,556 | $516,249 | 5 |
| DR PATRIK BRUNDIN | VARI ASSOCIATE DIRECTOR OF RESEARCH | 45 | $390,092 | $0 | $64,030 | $454,122 | 1 |
| DAVID WHITESCARVER | SECRETARY/ CHIEF LEGAL OFFICER | 50 | $303,113 | $0 | $92,727 | $395,840 | 1 |
| DR SCOTT JEWELL | INVESTIGATOR | 45 | $331,418 | $0 | $59,268 | $390,686 | 1 |
| LOVE COLLINS III | VICE PRESIDENT OF DEVELOPMENT, COMM., AND MKTG. | 45 | $271,344 | $0 | $82,732 | $354,076 | 1 |
| DR H ERIC XU | INVESTIGATOR | 45 | $283,371 | $0 | $54,007 | $337,378 | 1 |
| DR GEORGE VANDE WOUDE | TRUSTEE/ INVESTIGATOR | 50 | $300,227 | $0 | $26,410 | $326,637 | 1 |
| TIMOTHY MYERS | CHIEF FINANCIAL OFFICER | 50 | $231,533 | $0 | $70,637 | $302,170 | 5 |
| JOHN BENDER DONE 513 | CLINICAL OPERATIONS DIRECTOR | 45 | $249,080 | $0 | $50,158 | $299,238 | 1 |
| DR GISELLE SHOLLER DONE 613 | INVESTIGATOR | 45 | $248,918 | $0 | $43,267 | $292,185 | 1 |
| R JACK FRICK DONE 1211 | CHIEF ADMINISTRATIVE OFFICER | 0 | $273,377 | $0 | $0 | $273,377 | 1 |
| DR JANA HALL | CHIEF OPERATIONS OFFICER | 50 | $83,527 | $0 | $21,390 | $104,917 | 3 |
| DR GARY TARPLEY | TRUSTEE | 1 | $12,500 | $0 | $0 | $12,500 | 1 |
| DR JAMES FAHNER | TRUSTEE | 1 | $10,000 | $1,000 | $0 | $11,000 | 2 |
| DR RALPH WEICHSELBAUM | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
2011 · 16 people listed · 14 paid, $4.7M · 367 employees · 0 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| DR JEFFREY TRENTTHROUGH 312 | PRESIDENT & RESEARCH DIRECTOR | 50 | $1,180,739 | $0 | $243,940 | $1,424,679 | 1 |
| DAVID VAN ANDEL | CHAIRMAN / CEO | 28 | $411,467 | $0 | $122,461 | $533,928 | 5 |
| R JACK FRICK THROUGH 1211 | CHIEF ADMINISTRATIVE OFFICER | 50 | $275,769 | $0 | $95,458 | $371,227 | 1 |
| DR SCOTT JEWELL | DIST INVESTIGATOR | 45 | $296,776 | $0 | $65,194 | $361,970 | 1 |
| DR H ERIC XU | DIST INVESTIGATOR | 45 | $294,385 | $0 | $49,433 | $343,818 | 1 |
| DR GEORGE VANDE WOUDE | TRUSTEE/ DIST INVESTIGATOR | 50 | $299,763 | $0 | $25,940 | $325,703 | 1 |
| TIMOTHY MYERS | CHIEF FINANCIAL OFFICER | 50 | $237,174 | $0 | $78,801 | $315,975 | 5 |
| JOHN BENDER | CLINICAL OPERATIONS DIRECTOR | 45 | $235,889 | $0 | $49,192 | $285,081 | 2 |
| DR GISELLE SAULNIER SHOLLER | DIST INVESTIGATOR | 45 | $222,748 | $0 | $34,912 | $257,660 | 1 |
| DAVID WHITESCARVER | SECRETARY/ CHIEF LEGAL OFFICER | 50 | $197,281 | $0 | $49,962 | $247,243 | 1 |
| BRYON CAMPBELL | CHIEF INFORMATION OFFICER | 45 | $191,590 | $0 | $35,484 | $227,074 | 1 |
| DR FRITZ ROTTMAN PHD | TRUSTEE | 1 | $10,000 | $2,000 | $0 | $12,000 | 1 |
| DR JAMES FAHNER | TRUSTEE | 1 | $10,000 | $0 | $0 | $10,000 | 2 |
| WILLIAM POST THROUGH 312 | TRUSTEE | 1 | $2,000 | $0 | $0 | $2,000 | 1 |
| DR GARY TARPLEY | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| DR JANA HALL | CHIEF OPERATIONS OFFICER | 50 | $0 | $0 | $0 | $0 | 3 |
2010 · 17 people listed · 14 paid, $4.8M · 345 employees · 0 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| DR JEFFREY TRENT | PRESIDENT & RESEARCH DIREC | 50 | $1,043,405 | $0 | $303,030 | $1,346,435 | 4 |
| STEVE HEACOCK FORMER | CAO / GENERAL COUNSEL | 8 | $615,119 | $0 | $23,095 | $638,214 | 1 |
| DAVID VAN ANDEL | CHAIRMAN / CEO | 28 | $412,250 | $0 | $129,965 | $542,215 | 5 |
| GEORGE VANDE WOUDE | TRUSTEE/ DIST INVESTIGATOR | 50 | $325,763 | $0 | $44,345 | $370,108 | 1 |
| R JACK FRICK | CHIEF ADMINISTRATIVE OFFICER | 50 | $265,597 | $0 | $101,087 | $366,684 | 1 |
| DR H ERIC XU | DIST INVESTIGATOR | 45 | $267,231 | $0 | $48,773 | $316,004 | 1 |
| JOHN BENDER | CLINICAL OPERATIONS DIRECT | 45 | $233,240 | $0 | $31,603 | $264,843 | 2 |
| TIMOTHY MYERS | CHIEF FINANCIAL OFFICER | 50 | $156,599 | $0 | $90,958 | $247,557 | 5 |
| DR JAMES RESAU | DIST INVESTIGATOR | 45 | $192,433 | $0 | $39,977 | $232,410 | 1 |
| KATHLEEN VOGELSANG | DIR OF INVESTMENTS | 45 | $180,737 | $0 | $35,576 | $216,313 | 1 |
| BRYON CAMPBELL | CHIEF INFORMATION OFFICER | 45 | $179,498 | $0 | $35,557 | $215,055 | 1 |
| DR FRITZ ROTTMAN PHD | TRUSTEE | 1 | $10,000 | $2,000 | $0 | $12,000 | 1 |
| DR JAMES FAHNER | TRUSTEE | 1 | $10,000 | $0 | $0 | $10,000 | 2 |
| JOSE CARDENAS | TRUSTEE | 1 | $10,000 | $0 | $0 | $10,000 | 3 |
| WILLIAM POST | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 1 |
| JEFFREY BATTERSHALL | SECRETARY/ INTERIM CHIEF LEGAL | 1 | $0 | $0 | $0 | $0 | 1 |
| DAVID WHITESCARVER | SECRETARY/ CHIEF LEGAL OFFICER | 50 | $0 | $0 | $0 | $0 | 1 |
2009 · 18 people listed · 15 paid, $3.3M · 248 employees · 0 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| DAVID VAN ANDEL | Chairman / CEO | 40 | $414,308 | $0 | $39,326 | $453,634 | 5 |
| STEVE HEACOCK | CAO / GENERAL COUNSEL | 40 | $314,433 | $0 | $49,362 | $363,795 | 1 |
| GEORGE VANDE WOUDE | DIST Investigator | 40 | $320,002 | $0 | $41,487 | $361,489 | 1 |
| R JACK FRICK | CHIEF ADMINISTRATIVE OFFICER | 40 | $269,728 | $0 | $49,762 | $319,490 | 1 |
| KATHleen VOGELSANG | Dir of Investments | 40 | $251,394 | $0 | $20,221 | $271,615 | 1 |
| Ted Heilman | SR Portfolio Manager | 40 | $211,555 | $0 | $19,424 | $230,979 | 1 |
| Dr H Eric Xu | DIst Investigator | 40 | $199,344 | $0 | $22,373 | $221,717 | 1 |
| Joseph Gavan | VP-Communications & Development | 40 | $187,611 | $0 | $32,112 | $219,723 | 1 |
| Dr James Resau | Dist Investigator | 40 | $181,995 | $0 | $22,258 | $204,253 | 1 |
| BRYON CAMPBELL | CHIEF INFORMATION OFFICER | 40 | $179,709 | $0 | $21,433 | $201,142 | 1 |
| LINDA ZARZECKI | VICE PRESIDENT OF HUMAN RESOURCES | 40 | $143,913 | $0 | $18,841 | $162,754 | 1 |
| TIMOTHY MYERS | CHIEF FINANCIAL OFFICER | 40 | $137,189 | $0 | $18,371 | $155,560 | 5 |
| DR JEFFREY TRENT | PRESIDENT & RESEARCH DIRECTOR | 40 | $0 | $87,170 | $1,463 | $88,633 | 4 |
| Dr James Fahner | TRUSTEE | 1 | $15,000 | $0 | $0 | $15,000 | 2 |
| Dr FRITZ ROTTMAN PHD | TRUSTEE | 1 | $11,000 | $4,000 | $0 | $15,000 | 1 |
| JOSE CARDENAS | TRUSTEE | 1 | $0 | $0 | $0 | $0 | 3 |
| JEFFREY BATTERSHALL | SECRETARY | 1 | $0 | $0 | $0 | $0 | 1 |
| JOHN BENDER | CLINICAL OPERATIONS DIRECTOR | 40 | $0 | $0 | $0 | $0 | 2 |
Highest-paid independent contractors
2023 · 5 contractors · $3.6M
| Name | Location | Service | Paid |
|---|---|---|---|
| HURON CONSULTING GROUP INC | CHICAGO, IL | CONSULTING SERVICES | $1,804,360 |
| OWEN-AMES-KIMBALL CO | GRAND RAPIDS, MI | CONSTRUCTION SERVICES | $560,293 |
| MCPC INC | CLEVELAND, OH | HELPDESK SERVICES | $467,128 |
| FEI COMPANY | HILLSBORO, OR | MAINTENANCE SERVICES | $435,430 |
| TWO BY FOUR LTD | CHICAGO, IL | CONSULT. & ADVERT. SERVICES | $358,093 |
2022 · 5 contractors · $3.7M
| Name | Location | Service | Paid |
|---|---|---|---|
| HURON CONSULTING GROUP INC | CHICAGO, IL | CONSULTING SERVICES | $1,342,423 |
| TWO BY FOUR LTD | CHICAGO, IL | CONSULTING SERVICES | $1,261,455 |
| MCPC INC | CLEVELAND, OH | HELPDESK SERVICES | $512,623 |
| BLUEWATER TECHNOLOGIES INC | WIXOM, MI | AUDIO/VISUAL SERVICES | $321,032 |
| ILLUMINA | CHICAGO, IL | MAINTENANCE SERVICES | $294,577 |
2021 · 5 contractors · $2.2M
| Name | Location | Service | Paid |
|---|---|---|---|
| TWO BY FOUR LTD | CHICAGO, IL | CONSULTING SERVICES | $597,060 |
| BLUEWATER TECHNOLOGIES INC | WIXOM, MI | AUDIO/VISUAL SERVICES | $536,150 |
| MCPC INC | CLEVELAND, OH | HELPDESK SERVICES | $506,638 |
| WARNER NORCROSS & JUDD | GRAND RAPIDS, MI | ATTORNEY SERVICES | $279,693 |
| BUIST ELECTRIC CORPORATION | BYRON CENTER, MI | INSTALLATION SERVICES | $233,511 |
2020 · 5 contractors · $2.5M
| Name | Location | Service | Paid |
|---|---|---|---|
| WARNER NORCROSS & JUDD | GRAND RAPIDS, MI | ATTORNEY SERVICES | $1,021,286 |
| MCPC INC | CLEVELAND, OH | HELPDESK SERVICES | $519,109 |
| CISCO LESSEE DIRECT | WAYNE, PA | FINANCING SERVICES | $359,793 |
| TWO BY FOUR LTD | CHICAGO, IL | CONSULTING SERVICES | $322,752 |
| ALLIED UNIVERSAL SECURITY SERVICES | PHILADELPHIA, PA | SECURITY SERVICES | $291,253 |
2019 · 5 contractors · $1.6M
| Name | Location | Service | Paid |
|---|---|---|---|
| HOGAN LOVELLS US LLP | WASHINGTON, DC | ATTORNEY SERVICES | $523,385 |
| DE LAGE LANDEN FIN SVCS INC | WAYNE, PA | FINANCING SERVICES | $359,793 |
| ALLIED UNIVERSAL SECURITY SVCS | PHILADELPHIA, PA | SECURITY SERVICES | $301,714 |
| SECURALARM SYSTEMS INC | GRAND RAPIDS, MI | SECURITY SERVICES | $190,424 |
| ANDY J EGAN COMPANY INC | GRAND RAPIDS, MI | MAINTENANCE SERVICES | $189,566 |
2018 · 5 contractors · $1.3M
| Name | Location | Service | Paid |
|---|---|---|---|
| OWENS-AMES-KIMBALL CO | GRAND RAPIDS, MI | CONSTRUCTION SERVICES | $316,630 |
| DE LAGE LANDEN FIN SVCS INC | WAYNE, PA | EQUIPMENT LEASING | $301,452 |
| BLUE ROSE CAPITAL ADVISORS LLC | MINNEAPOLIS, MN | CONSULTING SERVICES | $298,000 |
| ALLIED UNIVERSAL SECURITY | PHILADELPHIA, PA | SECURITY SERVICES | $244,634 |
| FEDERAL EXPRESS | PITTSBURGH, PA | SHIPPING SERVICES | $189,276 |
2017 · 5 contractors · $1.0M
| Name | Location | Service | Paid |
|---|---|---|---|
| DK SECURITY INC | KENTWOOD, MI | SECURITY SERVICES | $305,357 |
| LOS ALAMOS NATIONAL LABORATORY | LOS ALAMOS, NM | SCIENTIFIC SERVICES | $242,520 |
| ANDY J EGAN COMPANY INC | GRAND RAPIDS, MI | MAINTENANCE SERVICES | $161,534 |
| FEDERAL EXPRESS | PITTSBURGH, PA | SHIPPING SERVICE | $151,422 |
| PRESIDIO NETWORK SOLUTIONS GROUP LLC | DALLAS, TX | CONSULTING SERVICES | $149,911 |
2016 · 5 contractors · $1.4M
| Name | Location | Service | Paid |
|---|---|---|---|
| PRESIDIO NETWORK SOLUTIONS GROUP LLC | DALLAS, TX | CONSULTING SERVICES | $394,030 |
| DK SECURITY INC | KENTWOOD, MI | SECURITY SERVICES | $310,903 |
| BECKMAN COULTER | PALATINE, IL | SERVICE CONTRACT | $262,610 |
| HONIGMAN MILLER SCHWARTZ LLC | DETROIT, MI | LEGAL / CONSULTING | $259,150 |
| TRANE | CHICAGO, IL | SERVICE CONTRACT | $147,718 |
2015 · 5 contractors · $1.2M
| Name | Location | Service | Paid |
|---|---|---|---|
| PRESIDIO INFRASTRUCTURE LLC | DALLAS, TX | CONSULTING SERVICES | $380,367 |
| DK SECURITY INC | KENTWOOD, MI | SECURITY SERVICES | $314,391 |
| FEDERAL EXPRESS | PITTSBURGH, PA | SHIPPING | $191,243 |
| HONIGMAN MILLER SCHWARTZ LLC | DETROIT, MI | LEGAL / CONSULTING | $184,580 |
| SECURALARM SYSTEMS INC | GRAND RAPIDS, MI | SECURITY SERVICES | $160,117 |
2014 · 5 contractors · $1.6M
| Name | Location | Service | Paid |
|---|---|---|---|
| CLARIENT DIAGNOSTIC SERVICES | LOS ANGELES, CA | SCIENTIFIC SERVICES | $560,280 |
| DK SECURITY INC | KENTWOOD, MI | SECURITY SERVICES | $390,529 |
| FEDERAL EXPRESS | PITTSBURGH, PA | SHIPPING | $255,699 |
| BLUEWATER TECHNOLOGIES INC | SOUTHFIELD, MI | AUDIO VISUAL SERVICES | $196,462 |
| HOGAN LOVELLS US LLP | WASHINGTON, DC | LEGAL / CONSULTING | $165,119 |
2013 · 5 contractors · $1.3M
| Name | Location | Service | Paid |
|---|---|---|---|
| DK SECURITY INC | SECURITY SERVICES | $384,716 | |
| HONIGMAN MILLER SCHWARTZ LLC | LEGAL/ CONSULTING | $271,701 | |
| FEDERAL EXPRESS | SHIPPING | $227,088 | |
| OLYMPIA ENTERTAINMENT INC | ADVERTISING | $225,300 | |
| FAIRLY PAINLESS ADVERTISING | ADVERTISING | $218,702 |
2012 · 5 contractors · $4.5M
| Name | Location | Service | Paid |
|---|---|---|---|
| BANK OF AMERICA | CHARLOTTE, NC | CREDIT ENHANCEMENT FEES | $3,393,605 |
| DK SECURITY INC | KENTWOOD, MI | SECURITY SERVICES | $363,304 |
| HONIGMAN MILLER SCHWARTZ LLC | ANN ARBOR, MI | LEGAL/ CONSULTING | $361,003 |
| WARNER NORCROSS & JUDD | GRAND RAPIDS, MI | LEGAL/ CONSULTING | $210,586 |
| CALLAHAN VENTURES LLC | GRAND RAPIDS, MI | CONSULTING | $194,206 |
2011 · 5 contractors · $5.3M
| Name | Location | Service | Paid |
|---|---|---|---|
| BANK OF AMERICAMERRILL LYNCH | CHARLOTTE, NC | CREDIT ENHANCEMENT FEES | $3,384,333 |
| AON RISK SERVICES CENTER INC | CHICAGO, IL | INSURANCE | $551,182 |
| WARNER NORCROSS & JUDD | GRAND RAPIDS, MI | LEGAL/ CONSULTING | $547,737 |
| PRIORITY HEALTH | CHICAGO, IL | HEALTH INSURANCE ADMIN | $464,179 |
| DK SECURITY | KENTWOOD, MI | SECURITY SERVICES | $370,952 |
2010 · 5 contractors · $17.4M
| Name | Location | Service | Paid |
|---|---|---|---|
| HUNT - OWEN AMES & KIMBALL (SEE SCHEDULE | SCOTTSDALE, AZ | CONSTRUCTION SERVICES | $12,393,896 |
| BANK OF AMERICAMERRILL LYNCH | CHARLOTTE, NC | CREDIT ENHANCEMENT FEES | $3,600,486 |
| AON RISK SERVICES CENTER INC | CHICAGO, IL | INSURANCE | $543,679 |
| WARNER NORCROSS & JUDD | GRAND RAPIDS, MI | LEGAL/ CONSULTING | $444,669 |
| DK SECURITY INC | KENTWOOD, MI | SECURITY SERVICES | $420,458 |
2009 · 5 contractors · $35.0M
| Name | Location | Service | Paid |
|---|---|---|---|
| HUNT - OWEN AMES & KIMBALL (See Schedule | SCOTTSDALE, AZ | CONSTRUCTION SERVICES | $32,089,485 |
| Bank of AmericaMerrill Lynch | Charlotte, NC | Credit Enhancement Fees | $1,135,277 |
| rafael vinoly pc | new york, NY | architecture/ design | $683,534 |
| translational genomics institute | phoenix, AZ | contract labor | $560,936 |
| warner norcross & judd | grand rapids, MI | legal/ consulting | $500,800 |
Federal grants and contracts
Awards from USAspending.gov to a recipient with this organization's name and zip code. Obligations by federal fiscal year (October to September); each award links to its page on usaspending.gov.
| Fiscal year | Grants and other assistance | Contracts | Awards |
|---|---|---|---|
| 2026 | $27,626,362 | $0 | 76 |
| 2025 | $26,895,438 | $0 | 67 |
| 2024 | $23,798,947 | $0 | 69 |
| 2023 | $29,937,921 | $0 | 74 |
| 2022 | $22,126,606 | $0 | 65 |
| 2021 | $23,530,902 | $0 | 60 |
| 2020 | $15,962,164 | $0 | 42 |
| 2019 | $18,239,042 | $0 | 45 |
| 2018 | $11,477,134 | $1,226,718 | 41 |
| 2017 | $11,085,817 | $0 | 28 |
| 2016 | $8,646,600 | $0 | 22 |
| 2015 | $7,027,817 | $0 | 19 |
| 2014 | $5,073,113 | $0 | 14 |
| 2013 | $3,251,055 | $0 | 11 |
| 2012 | $3,149,366 | $0 | 12 |
| 2011 | $2,234,728 | $0 | 9 |
| 2010 | $2,090,058 | $0 | 6 |
| 2008 | $1,049,551 | $0 | 3 |
| 2007 | $1,601,910 | $0 | 5 |
Largest awards · 200 shown
| Year | Agency | Kind | Program | Description | Obligated |
|---|---|---|---|---|---|
| 2026 | National Institutes of Health | Grant or other assistance | CANCER CAUSE AND PREVENTION RESEARCH 93.393 | MECHANISMS OF DNA METHYLATION SIGNALING AND DYSREGULATION IN COLON CANCER - PROJECT SUMMARY COLON CANCER IS A LEADING CAUSE OF CANCER-RELATED DEATH FOR BOTH MEN | $1,896,957 |
| 2026 | National Science Foundation | Grant or other assistance | BIOLOGICAL SCIENCES 47.074 | PPM: FUNCTIONAL ASYMMETRIES OF TRANS-HISTONE AND HISTONE-DNA CROSSTALK IN DEVELOPMENT -UNDERSTANDING HOW CELLS CONTROL GENE EXPRESSION IS A CENTRAL CHALLENGE IN | $1,500,000 |
| 2026 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | UNDERSTANDING PUTATIVE BETA-CELL SUBTYPES - PROJECT SUMMARY TYPE 2 DIABETES (T2D) IS A DISEASE THAT RESULTS FROM RELATIVE PANCREATIC Β-CELL DYSFUNCTION, AND AFF | $1,351,292 |
| 2026 | National Institutes of Health | Grant or other assistance | TRANS-NIH RESEARCH SUPPORT 93.310 | IDENTIFYING MICROBIAL MECHANISMS THAT REGULATE ANIMAL INSULIN SIGNALING - PROJECT SUMMARY INSULIN RESISTANCE AND TYPE 2 DIABETES AFFECT NEARLY 10% OF THE POPULA | $1,140,000 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER CAUSE AND PREVENTION RESEARCH 93.393 | TARGETING DNA METHYLATION AND THE CANCER EPIGENOME | $1,118,737 |
| 2026 | National Institutes of Health | Grant or other assistance | TRANS-NIH RESEARCH SUPPORT 93.310 | SINGLE-MOLECULE, SINGLE-CELL PROFILING OF CHROMATIN PROTEIN-PROTEIN INTERACTIONS. - PROJECT SUMMARY THE IMMUNE SYSTEM MUST BALANCE THE NEED TO ELIMINATE THREATS | $912,000 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | INVESTIGATING KDM5C AS A REGULATORY SWITCH BETWEEN ANABOLIC AND CATABOLIC METABOLISM - ABSTRACT CLONAL EXPANSION OF T CELLS IS A UNIQUE PHYSIOLOGICAL PROCESS AN | $886,437 |
| 2026 | Defense Health Agency | Grant or other assistance | MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 | REDUCING TOXICITY DRIVEN BY C9ORF72 REPEAT EXPANSIONS IN ALS | $840,000 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | DIET-MEDIATED REGULATION OF FATTY ACID SATURATION IMPACTS CANCER PROGRESSION AND THERAPY RESPONSES. - PROJECT SUMMARY/ABSTRACT MANY “ANTI-CANCER” DIETS ARE PRO | $796,798 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | METABOLIC TARGETING OF CD4 T CELLS IN CNS AUTOIMMUNITY - PROJECT SUMMARY/ABSTRACT INFLAMMATORY CD4 T HELPER (TH) CELLS ARE CENTRAL TO THE PATHOGENESIS OF MANY A | $790,222 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | ACCELERATED DNA METHYLATION ALTERATIONS IN HUTCHINSON-GILFORD PROGERIA SYNDROME - PROJECT SUMMARY / ABSTRACT HUTCHINSON-GILFORD PROGERIA SYNDROME (HGPS) IS A R | $783,592 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | DIETARY REGULATION OF ANTI-TUMOR IMMUNITY THROUGH CALORIC RESTRICTION - ABSTRACT OVERALL OBJECTIVE: THE FOOD WE EAT CAN AFFECT TUMOR GROWTH. YET, IT IS UNCLEAR | $767,324 |
| 2026 | National Institutes of Health | Grant or other assistance | MENTAL HEALTH RESEARCH GRANTS 93.242 | THE IMMUNOBIOLOGICAL MECHANISMS OF DEPRESSION IN PERIMENOPAUSE - PROJECT SUMMARY/ABSTRACT THIS PROJECT AIMS TO IDENTIFY IMMUNOBIOLOGICAL MECHANISMS UNDERLYING T | $765,613 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | CRYO-EM HIGH PERFORMANCE DATA STORAGE | $720,000 |
| 2026 | National Institutes of Health | Grant or other assistance | ENVIRONMENTAL HEALTH 93.113 | MOLECULAR MECHANISMS OF IAS-MEDIATED CARCINOGENESIS THROUGH THE LENS OF HISTONE H2B VARIANTS - ESTABLISHING THE INFLUENCE OF POLLUTANTS ON GENOME FUNCTION IS ES | $666,885 |
| 2026 | National Institutes of Health | Grant or other assistance | ENVIRONMENTAL HEALTH 93.113 | CIRCSATB2, A NOVEL REGULATOR OF ARSENIC-INDUCED CARCINOGENESIS - ABSTRACT INORGANIC ARSENIC (IAS) IS AN ENVIRONMENTALLY UBIQUITOUS TOXIN THAT AFFECTS >100 MILLI | $632,177 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | MECHANISMS AND APPLICATIONS OF RNA-MEDIATED ENZYMES IN TRANSLATION AND IMMUNITY - PROJECT SUMMARY DESCRIPTION: RNA-GUIDED, OR RIBONUCLEOPROTEIN PARTICLE (RNP), | $625,736 |
| 2026 | National Institutes of Health | Grant or other assistance | ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH 93.846 | SEXUALLY DIMORPHIC REGULATION OF BONE MASS BY THE X-LINKED HISTONE MODIFIER KDM5C - PROJECT SUMMARY/ABSTRACT WOMEN ARE DISPROPORTIONALLY SUSCEPTIBLE TO OSTEOPOR | $620,093 |
| 2026 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | STRUCTURAL BASIS OF PLAQUE MORPHOGENESIS IN ALZHEIMER'S DISEASE - PROJECT SUMMARY ALZHEIMER’S DISEASE (AD) IS THE MOST COMMON NEURODEGENERATIVE DISEASE, CHARACT | $618,967 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | ENDOGENOUS RETROVIRUS IN JOINT AGING AND OSTEOARTHRITIS DEVELOPMENT - PROJECT SUMMARY/ABSTRACT OSTEOARTHRITIS (OA) IS A DEGENERATIVE DISEASE OF THE JOINTS, THAT | $585,279 |
| 2026 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | NEURODEGENERATIVE MECHANISMS OF ATP13A2-LINKED PARKINSON'S DISEASE AND RELATED DISORDERS - PROJECT SUMMARY PARKINSON’S DISEASE (PD) AND KUFOR-RAKEB SYNDROME (KR | $582,465 |
| 2026 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | MECHANISMS OF GAIN-OF-REPEAT-TOXICITY AND LOSS-OF-C9ORF72-FUNCTION IN FTD AND ALS - PROJECT SUMMARY/ABSTRACT FRONTOTEMPORAL DEMENTIA (FTD) AND AMYOTROPHIC LATER | $555,128 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | MECHANISMS OF MUTANT MITOCHONDRIAL GENOME MODULATION - PROJECT SUMMARY/ABSTRACT EVER SINCE FORMING A SYMBIOTIC RELATIONSHIP WITH THE EUKARYOTIC HOST 2 BILLION Y | $529,298 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | REGULATION OF ENDOPLASMIC RETICULUM (ER) QUALITY CONTROL ACROSS CELL TYPES WITH UNIQUE ER MORPHOLOGIES. - PROJECT SUMMARY THE ENDOPLASMIC RETICULUM (ER) PERFORM | $528,000 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | REVEALING THE MOLECULAR BASIS OF MICROTUBULE-INTERMEDIATE FILAMENT INTERACTIONS. - PROJECT SUMMARY MICROTUBULES (MTS) AND INTERMEDIATE FILAMENTS (IFS) ARE TWO M | $528,000 |
| 2026 | National Institutes of Health | Grant or other assistance | CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 | DEVELOPMENTAL REPROGRAMMING BY GENE ENVIRONMENT INTERACTIONS - PROJECT SUMMARY THE DEVELOPMENTAL ORIGIN OF HEALTH AND DISEASE (DOHAD) HYPOTHESIS POSTULATES THAT | $528,000 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | MOLECULAR MECHANISMS OF CHROMATIN SIGNALING AND EPIGENETIC REGULATION - PROJECT SUMMARY DNA METHYLATION AND HISTONE POST-TRANSLATIONAL MODIFICATIONS (PTMS) ARE | $518,400 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER RESEARCH MANPOWER 93.398 | CANCER EPIGENETICS TRAINING (CET) PROGRAM - PROJECT SUMMARY THIS PROPOSAL SEEKS TO DEVELOP A DEDICATED CANCER EPIGENETICS TRAINING (CET) PROGRAM AT VAN ANDEL RE | $500,218 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | HARNESSING THE THERAPEUTIC POTENTIAL OF HISTOTRIPSY FOCUSED ULTRASOUND-INDUCED IMMUNOGENIC CANCER CELL DEATH - PROJECT SUMMARY/ABSTRACT IMMUNOTHERAPY CAN BE HI | $496,922 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER CAUSE AND PREVENTION RESEARCH 93.393 | MECHANISMS OF CANCER MUTATIONS - PROJECT SUMMARY: CANCER GENOME SEQUENCING HAS IDENTIFIED THOUSANDS OF SOMATIC MUTATIONS IN DIFFERENT TYPES OF HUMAN CANCER. THE | $482,549 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | ELUCIDATING THE STRUCTURAL MECHANISMS OF NAIP RECEPTORS IN BACTERIAL DETECTION AND INFLAMMASOME ACTIVATION - PROJECT SUMMARY INFLAMMASOMES ARE MEGA-DALTON PROT | $480,000 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | EPIGENETIC MECHANISMS OF RETROTRANSPOSON SILENCING - PROJECT SUMMARY/ABSTRACT RETROTRANSPOSONS ARE ANCIENT COMPONENTS OF OUR GENETIC CODE THAT HAVE SELF-REPLICA | $475,000 |
| 2026 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | MOLECULAR MECHANISMS FOR SORTING LYSOSOMAL PROTEINS - PROJECT SUMMARY THE OBJECTIVE OF THIS PROPOSAL IS TO GAIN MECHANISTIC AND PATHOLOGICAL UNDERSTANDING OF HU | $475,000 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | THE STRUCTURE AND FUNCTION OF EUKARYOTIC PROTEIN GLYCOSYLATION ENZYMES | $475,000 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | REGULATION OF MITOCHONDRIAL FATTY ACID SYNTHESIS IN THE CONTROL OF MITOCHONDRIAL METABOLISM. - PROJECT SUMMARY LIPIDS ARE IMPORTANT CELLULAR MACROMOLECULES THA | $475,000 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | NETWORK AND CELLULAR VULNERABILITY TO PATHOLOGICAL PROTEIN PROGRESSION - PROJECT SUMMARY/ABSTRACT OVER 6.5 MILLION PEOPLE IN THE UNITED STATES CURRENTLY LIVE WI | $440,318 |
| 2026 | National Institutes of Health | Grant or other assistance | CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 | FATTY ACID METABOLISM IN DISEASE MODELS OF MITOCHONDRIAL FATTY ACID SYNTHESIS DEFICIENCY. - TITLE: FATTY ACID METABOLISM IN DISEASE MODELS OF MITOCHONDRIAL FATT | $240,000 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | INVESTIGATING EPIGENETIC MECHANISMS OF CANCER - PROJECT SUMMARY DISRUPTIONS OF EPIGENETIC MECHANISMS THAT REGULATE GENE EXPRESSION ARE FREQUENTLY FOUND IN CANCE | $204,106 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER RESEARCH MANPOWER 93.398 | ONCOPROTEIN-REGULATED LINEAGE PLASTICITY IN ACUTE LEUKEMIA - ABSTRACT CHROMOSOMAL TRANSLOCATIONS INVOLVING THE LYSINE METHYLTRANSFERASE 2A (KMT2A) GENE ARE COMM | $192,240 |
| 2026 | National Institutes of Health | Grant or other assistance | TRANS-NIH RESEARCH SUPPORT 93.310 | DEVELOPMENT AND IMPROVEMENT OF RESEARCH SOFTWARE FOR DNA METHYLATION AND RNA SEQUENCING ANALYSIS - PROJECT SUMMARY I AM A RESEARCH SOFTWARE ENGINEER IN DR. HUI | $190,764 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | THE ROLE OF AHR IN MODULATINGIMMUNOTHERAPY RESPONSE AND ADVERSE EVENTS IN BLADDER CANCER - PROJECT SUMMARY ONE HALLMARK OF CANCER IS A TUMOR’S ABILITY TO EVADE | $183,769 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER CAUSE AND PREVENTION RESEARCH 93.393 | RESEARCH SPECIALIST SUPPORT-TARGETING DNA METHYLATION AND THE CANCER EPIGENOME | $166,080 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | REGULATION OF DNA METHYLATION INHERITANCE IN COLON CANCER - PROJECT SUMMARY DISRUPTIONS IN THE MECHANISMS THAT MAINTAIN DNA METHYLATION PATTERNS ARE A HALLMARK | $119,105 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER RESEARCH MANPOWER 93.398 | TARGETING PTGIR-PROSTACYCLIN SIGNALING TO OVERCOME T CELL EXHAUSTION AND ENHANCE ANTI-TUMOR IMMUNITY - PROJECT SUMMARY CONTINUOUS EXPOSURE TO CANCER ANTIGENS CA | $112,234 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER CAUSE AND PREVENTION RESEARCH 93.393 | TARGETING MECHANISMS OF CHROMATIN PLASTICITY TO IMPROVE THE EFFICACY OF EPIGENETIC SOLID TUMOR THERAPY - PROJECT SUMMARY ABERRANT DNA METHYLATION IS A HALLMARK | $55,114 |
| 2026 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | DISSECTING NEURONAL MOLECULAR TRAJECTORIES AND GLIAL RESPONSES TO Α-SYNUCLEIN AGGREGATES IN LEWY BODY DISEASES - ABSTRACT LEWY BODY DISEASES (LBDS) INCLUDING PA | $52,114 |
| 2026 | National Institutes of Health | Grant or other assistance | HUMAN GENOME RESEARCH 93.172 | EPIGENOMICS WORKSHOP FOR GRADUATE STUDENTS - PROJECT SUMMARY THE FIELD OF EPIGENOMICS IS EXPANDING RAPIDLY, DRIVEN IN LARGE PART BY NEW AND EVOLVING TECHNOLOGY, | $51,777 |
| 2026 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | UPSTREAM REQUIREMENTS FOR THE REGULATION OF MITOCHONDRIAL BIOENERGETICS BY THE MITOCHONDRIAL ACYL CARRIER PROTEIN - PROJECT SUMMARY RECENT ADVANCES IN CELL BIO | $49,114 |
| 2026 | National Institutes of Health | Grant or other assistance | CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 | MIDWEST ZEBRAFISH MEETING 2026 - PROJECT SUMMARY THE MIDWEST ZEBRAFISH MEETING (MWZM) IS A BIENNIAL SCIENTIFIC CONFERENCE THAT BRINGS TOGETHER RESEARCHERS USING | $20,000 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | UNDERSTANDING THE EFFECTS OF DIETARY INTERVENTIONS ON PANCREATIC DUCTAL ADENOCARCINOMA THERAPY CANCER - PROJECT SUMMARY/ABSTRACT PANCREATIC DUCTAL ADENOCARCINO | $0 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | HIGH-THROUGHPUT EPIGENOMIC MAPPING OF REGULATORY ELEMENTS IN OVARIAN CANCER AT BASEPAIR RESOLUTION | -$16,425 |
| 2026 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | CORTICAL NEURONAL VULNERABILITY IN PARKINSON'S DISEASE - ABSTRACT PARKINSON’S DISEASE (PD) IS A DEBILITATING, PROGRESSIVE NEUROLOGICAL DISEASE CHARACTERIZED BY | -$35,678 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | IDENTIFYING DETERMINANTS OF TAU PATHOLOGY SEEDING - PROJECT SUMMARY/ABSTRACT ALZHEIMER'S DISEASE (AD) IS THE MOST COMMON NEURODEGENERATIVE DISORDER IN THE UNIT | -$45,358 |
| 2025 | National Institutes of Health | Grant or other assistance | TRANS-NIH RESEARCH SUPPORT 93.310 | MASTER REGULATORS OF UNEXPLAINED VARIATION IN DISEASE RISK - PROJECT SUMMARY PRECISION MEDICINE REQUIRES AN UNDERSTANDING OF THE ORIGINS AND MOLECULAR CONTROL O | $1,928,796 |
| 2025 | National Institutes of Health | Grant or other assistance | ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH 93.846 | MITOCHONDRIAL OXIDATIVE METABOLISM IS A CRITICAL DETERMINANT OF MUSCLE SATELLITE CELL FATE & FUNCTION - MUSCLE STEM CELLS (MUSCS) GIVE SKELETAL MUSCLE THE REMAR | $1,622,775 |
| 2025 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | KETONE BODY METABOLISM IN CD8+ T CELL RESPONSES - ABSTRACT IT HAS BEEN BELIEVED THAT INFECTION-FIGHTING T CELLS PRIMARILY USE GLUCOSE TO FUEL HOST DEFENSE AGAIN | $1,301,502 |
| 2025 | National Institutes of Health | Grant or other assistance | CANCER CAUSE AND PREVENTION RESEARCH 93.393 | TARGETING DNA METHYLATION AND THE CANCER EPIGENOME | $1,022,083 |
| 2025 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | A NOVEL GENE THERAPY APPROACH TO REDUCE NEUROTOXICITY IN PARKINSON'S DISEASE - PROJECT SUMMARY/ABSTRACT PARKINSON’S DISEASE (PD) IS A COMMON NEURODEGENERATIVE D | $1,009,212 |
| 2025 | National Institutes of Health | Grant or other assistance | MENTAL HEALTH RESEARCH GRANTS 93.242 | THE IMMUNOBIOLOGICAL MECHANISMS OF DEPRESSION IN PERIMENOPAUSE - PROJECT SUMMARY/ABSTRACT THIS PROJECT AIMS TO IDENTIFY IMMUNOBIOLOGICAL MECHANISMS UNDERLYING T | $919,453 |
| 2025 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | DIET-MEDIATED REGULATION OF FATTY ACID SATURATION IMPACTS CANCER PROGRESSION AND THERAPY RESPONSES. - PROJECT SUMMARY/ABSTRACT MANY “ANTI-CANCER” DIETS ARE PRO | $796,798 |
| 2025 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | METABOLIC TARGETING OF CD4 T CELLS IN CNS AUTOIMMUNITY - PROJECT SUMMARY/ABSTRACT INFLAMMATORY CD4 T HELPER (TH) CELLS ARE CENTRAL TO THE PATHOGENESIS OF MANY A | $790,222 |
| 2025 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | ACCELERATED DNA METHYLATION ALTERATIONS IN HUTCHINSON-GILFORD PROGERIA SYNDROME - PROJECT SUMMARY / ABSTRACT HUTCHINSON-GILFORD PROGERIA SYNDROME (HGPS) IS A R | $770,473 |
| 2025 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | DIETARY REGULATION OF ANTI-TUMOR IMMUNITY THROUGH CALORIC RESTRICTION - ABSTRACT OVERALL OBJECTIVE: THE FOOD WE EAT CAN AFFECT TUMOR GROWTH. YET, IT IS UNCLEAR | $767,324 |
| 2025 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | CRYO-EM HIGH PERFORMANCE DATA STORAGE | $720,000 |
| 2025 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | UNDERSTANDING PUTATIVE BETA-CELL SUBTYPES - PROJECT SUMMARY TYPE 2 DIABETES (T2D) IS A DISEASE THAT RESULTS FROM RELATIVE PANCREATIC Β-CELL DYSFUNCTION, AND AFF | $675,646 |
| 2025 | National Institutes of Health | Grant or other assistance | ENVIRONMENTAL HEALTH 93.113 | MOLECULAR MECHANISMS OF IAS-MEDIATED CARCINOGENESIS THROUGH THE LENS OF HISTONE H2B VARIANTS - ESTABLISHING THE INFLUENCE OF POLLUTANTS ON GENOME FUNCTION IS ES | $655,853 |
| 2025 | National Institutes of Health | Grant or other assistance | ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH 93.846 | SEXUALLY DIMORPHIC REGULATION OF BONE MASS BY THE X-LINKED HISTONE MODIFIER KDM5C - PROJECT SUMMARY/ABSTRACT WOMEN ARE DISPROPORTIONALLY SUSCEPTIBLE TO OSTEOPOR | $633,147 |
| 2025 | National Institutes of Health | Grant or other assistance | CANCER CAUSE AND PREVENTION RESEARCH 93.393 | MECHANISMS OF DNA METHYLATION SIGNALING AND DYSREGULATION IN COLON CANCER - PROJECT SUMMARY COLON CANCER IS A LEADING CAUSE OF CANCER-RELATED DEATH FOR BOTH MEN | $632,319 |
| 2025 | National Institutes of Health | Grant or other assistance | ENVIRONMENTAL HEALTH 93.113 | CIRCSATB2, A NOVEL REGULATOR OF ARSENIC-INDUCED CARCINOGENESIS - ABSTRACT INORGANIC ARSENIC (IAS) IS AN ENVIRONMENTALLY UBIQUITOUS TOXIN THAT AFFECTS >100 MILLI | $628,913 |
| 2025 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | MECHANISMS AND APPLICATIONS OF RNA-MEDIATED ENZYMES IN TRANSLATION AND IMMUNITY - PROJECT SUMMARY DESCRIPTION: RNA-GUIDED, OR RIBONUCLEOPROTEIN PARTICLE (RNP), | $625,736 |
| 2025 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | A TRIM28-ERV AXIS DRIVES PHENOTYPIC VARIATION IN OBESITY - MODIFIED PROJECT SUMMARY/ABSTRACT SECTION ESTIMATES FROM TWIN AND INBRED ANIMAL MODELS SUGGEST THAT | $600,000 |
| 2025 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | ENDOGENOUS RETROVIRUS IN JOINT AGING AND OSTEOARTHRITIS DEVELOPMENT - PROJECT SUMMARY/ABSTRACT OSTEOARTHRITIS (OA) IS A DEGENERATIVE DISEASE OF THE JOINTS, THAT | $573,573 |
| 2025 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | LINEAGE-TRACED SINGLE-CELL ANALYSIS OF EPIGENETIC CLOCKS - PROJECT SUMMARY / ABSTRACT IT HAS LONG BEEN KNOWN THAT DNA METHYLATION PROFILES IN THE GENOME PROGRE | $528,000 |
| 2025 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | REVEALING THE MOLECULAR BASIS OF MICROTUBULE-INTERMEDIATE FILAMENT INTERACTIONS. - PROJECT SUMMARY MICROTUBULES (MTS) AND INTERMEDIATE FILAMENTS (IFS) ARE TWO M | $528,000 |
| 2025 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | STRUCTURAL BASIS OF NOCICEPTOR CHANNEL TRPM3 GATING AND PHARMACOLOGY - PROJECT SUMMARY THE DETECTION AND RAPID AVOIDANCE OF HARMFUL EXTERNAL STIMULI VIA PAIN PE | $521,959 |
| 2025 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | A NOVEL PROCESS SAFEGUARDS GENOME INTEGRITY IN THE MAMMALIAN GERM LINE - PROJECT SUMMARY SIMPLE PURINE–PYRIMIDINE (PU/PY) REPEATS (PPRS) ARE KNOWN TO FORM THE L | $519,036 |
| 2025 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | MOLECULAR MECHANISMS OF CHROMATIN SIGNALING AND EPIGENETIC REGULATION - PROJECT SUMMARY DNA METHYLATION AND HISTONE POST-TRANSLATIONAL MODIFICATIONS (PTMS) ARE | $518,400 |
| 2025 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | HARNESSING THE THERAPEUTIC POTENTIAL OF HISTOTRIPSY FOCUSED ULTRASOUND-INDUCED IMMUNOGENIC CANCER CELL DEATH - PROJECT SUMMARY/ABSTRACT IMMUNOTHERAPY CAN BE HI | $496,811 |
| 2025 | National Institutes of Health | Grant or other assistance | CANCER RESEARCH MANPOWER 93.398 | CANCER EPIGENETICS TRAINING (CET) PROGRAM - PROJECT SUMMARY THIS PROPOSAL SEEKS TO DEVELOP A DEDICATED CANCER EPIGENETICS TRAINING (CET) PROGRAM AT VAN ANDEL RE | $494,901 |
| 2025 | National Institutes of Health | Grant or other assistance | CANCER CAUSE AND PREVENTION RESEARCH 93.393 | MECHANISMS OF CANCER MUTATIONS - PROJECT SUMMARY: CANCER GENOME SEQUENCING HAS IDENTIFIED THOUSANDS OF SOMATIC MUTATIONS IN DIFFERENT TYPES OF HUMAN CANCER. THE | $482,549 |
| 2025 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | UNDERSTANDING WNT9A/FZD9 TRAFFICKING AND SIGNALING - CELL TO CELL SIGNALING IS FUNDAMENTAL TO ALL MULTICELLULAR LIFE. SECRETED SIGNALING MOLECULES FROM ONE CELL | $475,000 |
| 2025 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | EPIGENETIC MECHANISMS OF RETROTRANSPOSON SILENCING - PROJECT SUMMARY/ABSTRACT RETROTRANSPOSONS ARE ANCIENT COMPONENTS OF OUR GENETIC CODE THAT HAVE SELF-REPLICA | $475,000 |
| 2025 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | MOLECULAR MECHANISMS FOR SORTING LYSOSOMAL PROTEINS - PROJECT SUMMARY THE OBJECTIVE OF THIS PROPOSAL IS TO GAIN MECHANISTIC AND PATHOLOGICAL UNDERSTANDING OF HU | $475,000 |
| 2025 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | REGULATION OF MITOCHONDRIAL FATTY ACID SYNTHESIS IN THE CONTROL OF MITOCHONDRIAL METABOLISM. - PROJECT SUMMARY LIPIDS ARE IMPORTANT CELLULAR MACROMOLECULES THA | $475,000 |
| 2025 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | THE STRUCTURE AND FUNCTION OF EUKARYOTIC PROTEIN GLYCOSYLATION ENZYMES | $475,000 |
| 2025 | National Institutes of Health | Grant or other assistance | CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 | INTEGRATIVE CANCER EPIGENOMIC DATA ANALYSIS CENTER (ICE-DAC) - PROJECT SUMMARY / ABSTRACT THE WIDESPREAD NATURE OF EPIGENETIC ABNORMALITIES IN HUMAN CANCERS HA | $456,000 |
| 2025 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | HIGH THROUGHPUT SCREEN FOR INHIBITORS OF THE YEATS2 HISTONE ACYLATION READER - PROJECT SUMMARY LUNG CANCER IS THE LEADING CAUSE OF CANCER-RELATED DEATHS IN BOTH | $434,625 |
| 2025 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | NETWORK AND CELLULAR VULNERABILITY TO PATHOLOGICAL PROTEIN PROGRESSION - PROJECT SUMMARY/ABSTRACT OVER 6.5 MILLION PEOPLE IN THE UNITED STATES CURRENTLY LIVE WI | $432,333 |
| 2025 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | LRRK2 ENZYMATIC MECHANISMS OF NEURODEGENERATION IN PARKINSON'S DISEASE - PROJECT SUMMARY PARKINSON'S DISEASE (PD) IS A PROGRESSIVE NEURODEGENERATIVE MOVEMENT DI | $427,500 |
| 2025 | National Institutes of Health | Grant or other assistance | ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH 93.846 | 5-METHYLCYTOSINE OXIDATION IN DEVELOPMENT AND DISEASE - PROJECT SUMMARY: 5-METHYLCYTOSINE OXIDATION IN DEVELOPMENT AND DISEASE DNA METHYLATION AT GENE PROMOTERS | $405,460 |
| 2025 | National Science Foundation | Grant or other assistance | BIOLOGICAL SCIENCES 47.074 | MECHANISMS OF DEVELOPMENTAL PLASTICITY -WHILE DEVELOPMENTAL EVENTS ARE GENERALLY TIGHTLY CONTROLLED DURING EMBRYOGENESIS, A CERTAIN LEVEL OF FLEXIBILITY EXISTS. | $400,000 |
| 2025 | National Institutes of Health | Grant or other assistance | CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 | FATTY ACID METABOLISM IN DISEASE MODELS OF MITOCHONDRIAL FATTY ACID SYNTHESIS DEFICIENCY. - TITLE: FATTY ACID METABOLISM IN DISEASE MODELS OF MITOCHONDRIAL FATT | $288,000 |
| 2025 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | THE ROLE OF AHR IN MODULATINGIMMUNOTHERAPY RESPONSE AND ADVERSE EVENTS IN BLADDER CANCER - PROJECT SUMMARY ONE HALLMARK OF CANCER IS A TUMOR’S ABILITY TO EVADE | $249,000 |
| 2025 | National Institutes of Health | Grant or other assistance | CANCER RESEARCH MANPOWER 93.398 | ONCOPROTEIN-REGULATED LINEAGE PLASTICITY IN ACUTE LEUKEMIA - ABSTRACT CHROMOSOMAL TRANSLOCATIONS INVOLVING THE LYSINE METHYLTRANSFERASE 2A (KMT2A) GENE ARE COMM | $192,240 |
| 2025 | National Institutes of Health | Grant or other assistance | CANCER CAUSE AND PREVENTION RESEARCH 93.393 | RESEARCH SPECIALIST SUPPORT-TARGETING DNA METHYLATION AND THE CANCER EPIGENOME | $166,080 |
| 2025 | National Institutes of Health | Grant or other assistance | CANCER RESEARCH MANPOWER 93.398 | THE ROLE OF AHR IN MODULATINGIMMUNOTHERAPY RESPONSE AND ADVERSE EVENTS IN BLADDER CANCER - PROJECT SUMMARY ONE HALLMARK OF CANCER IS A TUMOR’S ABILITY TO EVADE | $153,160 |
| 2025 | National Institutes of Health | Grant or other assistance | CANCER RESEARCH MANPOWER 93.398 | TARGETING PTGIR-PROSTACYCLIN SIGNALING TO OVERCOME T CELL EXHAUSTION AND ENHANCE ANTI-TUMOR IMMUNITY - PROJECT SUMMARY CONTINUOUS EXPOSURE TO CANCER ANTIGENS CA | $112,234 |
| 2025 | National Institutes of Health | Grant or other assistance | ORAL DISEASES AND DISORDERS RESEARCH 93.121 | DECIPHERING THE ROLE OF FRIZZLED RECEPTORS IN PALATAL DEVELOPMENT - PROJECT SUMMARY/ABSTRACT CLEFT LIP AND/OR CLEFT PALATE HAS AN INCIDENCE OF APPROXIMATELY 1 I | $109,274 |
| 2025 | National Institutes of Health | Grant or other assistance | CANCER RESEARCH MANPOWER 93.398 | A MOLECULAR CASE SERIES: DEEP CELLULAR AND SPATIAL EPIGENETIC CHARACTERIZATION OF HUMAN COLORECTAL CANCER - PROJECT SUMMARY/ABSTRACT CANCER HAS LONG BEEN THOUG | $54,538 |
| 2025 | National Institutes of Health | Grant or other assistance | CANCER CAUSE AND PREVENTION RESEARCH 93.393 | DETERMINANTS OF SUSCEPTIBILITY TO PEDIATRIC ACUTE MYELOID LEUKEMIA - F99CA294248 PI: LAUREN HARMON ADMINISTRATIVE SUPPLEMENT FOR FELLOWSHIP AWARD – CHILDCARE CO | $54,538 |
| 2025 | National Science Foundation | Grant or other assistance | STEM EDUCATION (FORMERLY EDUCATION AND HUMAN RESOURCES) 47.076 | GRADUATE RESEARCH FELLOWSHIP PROGRAM (GRFP) -THE NATIONAL SCIENCE FOUNDATION (NSF) GRADUATE RESEARCH FELLOWSHIP PROGRAM (GRFP) IS A HIGHLY COMPETITIVE, FEDERAL | $53,000 |
| 2025 | National Institutes of Health | Grant or other assistance | HUMAN GENOME RESEARCH 93.172 | EPIGENOMICS WORKSHOP FOR GRADUATE STUDENTS - PROJECT SUMMARY THE FIELD OF EPIGENOMICS IS EXPANDING RAPIDLY, DRIVEN IN LARGE PART BY NEW AND EVOLVING TECHNOLOGY, | $51,777 |
| 2025 | National Institutes of Health | Grant or other assistance | CANCER CAUSE AND PREVENTION RESEARCH 93.393 | TARGETING MECHANISMS OF CHROMATIN PLASTICITY TO IMPROVE THE EFFICACY OF EPIGENETIC SOLID TUMOR THERAPY - PROJECT SUMMARY ABERRANT DNA METHYLATION IS A HALLMARK | $50,038 |
| 2025 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | IDENTIFYING DETERMINANTS OF TAU PATHOLOGY SEEDING - PROJECT SUMMARY/ABSTRACT ALZHEIMER'S DISEASE (AD) IS THE MOST COMMON NEURODEGENERATIVE DISORDER IN THE UNIT | $48,538 |
| 2025 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | UPSTREAM REQUIREMENTS FOR THE REGULATION OF MITOCHONDRIAL BIOENERGETICS BY THE MITOCHONDRIAL ACYL CARRIER PROTEIN - PROJECT SUMMARY RECENT ADVANCES IN CELL BIO | $48,538 |
| 2025 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | CORTICAL NEURONAL VULNERABILITY IN PARKINSON'S DISEASE - ABSTRACT PARKINSON’S DISEASE (PD) IS A DEBILITATING, PROGRESSIVE NEUROLOGICAL DISEASE CHARACTERIZED BY | $48,538 |
| 2025 | National Institutes of Health | Grant or other assistance | CANCER CAUSE AND PREVENTION RESEARCH 93.393 | IMPACT OF NEUROFIBROMIN ON ER-ALPHA AND NUCLEAR SPECK POST-TRANSCRIPTIONAL GENE REGULATION - PROJECT SUMMARY ALTERNATIVE SPLICING (AS) OF TRANSCRIPTS IS AN ESS | -$10,870 |
| 2025 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | STRUCTURAL AND FUNCTIONAL STUDIES OF CALHM CHANNELS | -$37,500 |
| 2025 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | ELUCIDATING STRUCTURES AND MOLECULAR MECHANISMS OF PANNEXIN CHANNELS | -$68,210 |
| 2025 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | THE ROLES OF GENETICS, HORMONES, AND GENDER IN SEXUALLY DIMORPHIC IMMUNE RESPONSE - ABSTRACT SEX AND GENDER CONTRIBUTE TO THE IMMUNE SYSTEM AND HOW WE AS HUMANS | -$361,874 |
| 2024 | National Institutes of Health | Grant or other assistance | TRANS-NIH RESEARCH SUPPORT 93.310 | MASTER REGULATORS OF UNEXPLAINED VARIATION IN DISEASE RISK - PROJECT SUMMARY PRECISION MEDICINE REQUIRES AN UNDERSTANDING OF THE ORIGINS AND MOLECULAR CONTROL O | $1,928,798 |
| 2024 | National Institutes of Health | Grant or other assistance | CANCER CAUSE AND PREVENTION RESEARCH 93.393 | TARGETING DNA METHYLATION AND THE CANCER EPIGENOME | $1,065,709 |
| 2024 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | DIET-MEDIATED REGULATION OF FATTY ACID SATURATION IMPACTS CANCER PROGRESSION AND THERAPY RESPONSES. - PROJECT SUMMARY/ABSTRACT MANY “ANTI-CANCER” DIETS ARE PRO | $796,798 |
| 2024 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | ACCELERATED DNA METHYLATION ALTERATIONS IN HUTCHINSON-GILFORD PROGERIA SYNDROME - PROJECT SUMMARY / ABSTRACT HUTCHINSON-GILFORD PROGERIA SYNDROME (HGPS) IS A R | $786,197 |
| 2024 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | STRUCTURAL BASIS OF NOCICEPTOR CHANNEL TRPM3 GATING AND PHARMACOLOGY - PROJECT SUMMARY THE DETECTION AND RAPID AVOIDANCE OF HARMFUL EXTERNAL STIMULI VIA PAIN PE | $740,104 |
| 2024 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | CRYO-EM HIGH PERFORMANCE DATA STORAGE | $720,000 |
| 2024 | National Science Foundation | Grant or other assistance | BIOLOGICAL SCIENCES 47.074 | MECHANISMS OF DEVELOPMENTAL PLASTICITY -WHILE DEVELOPMENTAL EVENTS ARE GENERALLY TIGHTLY CONTROLLED DURING EMBRYOGENESIS, A CERTAIN LEVEL OF FLEXIBILITY EXISTS. | $700,000 |
| 2024 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | UNDERSTANDING PUTATIVE BETA-CELL SUBTYPES - PROJECT SUMMARY TYPE 2 DIABETES (T2D) IS A DISEASE THAT RESULTS FROM RELATIVE PANCREATIC Β-CELL DYSFUNCTION, AND AFF | $698,646 |
| 2024 | National Institutes of Health | Grant or other assistance | ENVIRONMENTAL HEALTH 93.113 | MOLECULAR MECHANISMS OF IAS-MEDIATED CARCINOGENESIS THROUGH THE LENS OF HISTONE H2B VARIANTS - ESTABLISHING THE INFLUENCE OF POLLUTANTS ON GENOME FUNCTION IS ES | $678,587 |
| 2024 | National Institutes of Health | Grant or other assistance | ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH 93.846 | SEXUALLY DIMORPHIC REGULATION OF BONE MASS BY THE X-LINKED HISTONE MODIFIER KDM5C - PROJECT SUMMARY/ABSTRACT WOMEN ARE DISPROPORTIONALLY SUSCEPTIBLE TO OSTEOPOR | $652,729 |
| 2024 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | KETONE BODY METABOLISM IN CD8+ T CELL RESPONSES - ABSTRACT IT HAS BEEN BELIEVED THAT INFECTION-FIGHTING T CELLS PRIMARILY USE GLUCOSE TO FUEL HOST DEFENSE AGAIN | $650,751 |
| 2024 | National Institutes of Health | Grant or other assistance | CANCER CAUSE AND PREVENTION RESEARCH 93.393 | MECHANISMS OF DNA METHYLATION SIGNALING AND DYSREGULATION IN COLON CANCER - PROJECT SUMMARY COLON CANCER IS A LEADING CAUSE OF CANCER-RELATED DEATH FOR BOTH MEN | $632,319 |
| 2024 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | THE ROLES OF GENETICS, HORMONES, AND GENDER IN SEXUALLY DIMORPHIC IMMUNE RESPONSE - ABSTRACT SEX AND GENDER CONTRIBUTE TO THE IMMUNE SYSTEM AND HOW WE AS HUMANS | $610,938 |
| 2024 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | ENDOGENOUS RETROVIRUS IN JOINT AGING AND OSTEOARTHRITIS DEVELOPMENT - PROJECT SUMMARY/ABSTRACT OSTEOARTHRITIS (OA) IS A DEGENERATIVE DISEASE OF THE JOINTS, THAT | $610,479 |
| 2024 | National Institutes of Health | Grant or other assistance | ENVIRONMENTAL HEALTH 93.113 | CIRCSATB2, A NOVEL REGULATOR OF ARSENIC-INDUCED CARCINOGENESIS - ABSTRACT INORGANIC ARSENIC (IAS) IS AN ENVIRONMENTALLY UBIQUITOUS TOXIN THAT AFFECTS >100 MILLI | $604,923 |
| 2024 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | PROGRESSIVE DNA HYPOMETHYLATION AS A MEASURE OF MITOTIC HISTORY AND POTENTIAL CONTRIBUTOR TO REPLICATIVE SENESCENCE. | $597,032 |
| 2024 | National Institutes of Health | Grant or other assistance | ENVIRONMENTAL HEALTH 93.113 | MOLECULAR MECHANISMS UNDERLYING METABOLIC REPROGRAMMING BY PATERNAL BENZENE EXPOSURE - ABSTRACT THERE IS A MAJOR GAP IN OUR UNDERSTANDING OF HOW PATERNAL EXPERI | $586,660 |
| 2024 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | A TRIM28-ERV AXIS DRIVES PHENOTYPIC VARIATION IN OBESITY - MODIFIED PROJECT SUMMARY/ABSTRACT SECTION ESTIMATES FROM TWIN AND INBRED ANIMAL MODELS SUGGEST THAT | $575,999 |
| 2024 | National Institutes of Health | Grant or other assistance | ENVIRONMENTAL HEALTH 93.113 | MOLECULAR UNDERPINNINGS IN THE ESTABLISHMENT OF AN ONCOGENIC 3D GENOME IN RESPONSE TO ENVIRONMENTAL ARSENIC EXPOSURE | $565,039 |
| 2024 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | MECHANISMS AND APPLICATIONS OF RNA-MEDIATED ENZYMES IN TRANSLATION AND IMMUNITY - PROJECT SUMMARY DESCRIPTION: RNA-GUIDED, OR RIBONUCLEOPROTEIN PARTICLE (RNP), | $537,379 |
| 2024 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | A NOVEL PROCESS SAFEGUARDS GENOME INTEGRITY IN THE MAMMALIAN GERM LINE - PROJECT SUMMARY SIMPLE PURINE–PYRIMIDINE (PU/PY) REPEATS (PPRS) ARE KNOWN TO FORM THE L | $519,036 |
| 2024 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | MOLECULAR MECHANISMS OF CHROMATIN SIGNALING AND EPIGENETIC REGULATION - PROJECT SUMMARY DNA METHYLATION AND HISTONE POST-TRANSLATIONAL MODIFICATIONS (PTMS) ARE | $518,400 |
| 2024 | National Institutes of Health | Grant or other assistance | CANCER RESEARCH MANPOWER 93.398 | CANCER EPIGENETICS TRAINING (CET) PROGRAM - PROJECT SUMMARY THIS PROPOSAL SEEKS TO DEVELOP A DEDICATED CANCER EPIGENETICS TRAINING (CET) PROGRAM AT VAN ANDEL RE | $477,477 |
| 2024 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | UNDERSTANDING WNT9A/FZD9 TRAFFICKING AND SIGNALING - CELL TO CELL SIGNALING IS FUNDAMENTAL TO ALL MULTICELLULAR LIFE. SECRETED SIGNALING MOLECULES FROM ONE CELL | $475,000 |
| 2024 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | REGULATION OF MITOCHONDRIAL FATTY ACID SYNTHESIS IN THE CONTROL OF MITOCHONDRIAL METABOLISM. - PROJECT SUMMARY LIPIDS ARE IMPORTANT CELLULAR MACROMOLECULES THA | $475,000 |
| 2024 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | ELUCIDATING STRUCTURES AND MOLECULAR MECHANISMS OF PANNEXIN CHANNELS | $475,000 |
| 2024 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | EPIGENETIC MECHANISMS OF RETROTRANSPOSON SILENCING - PROJECT SUMMARY/ABSTRACT RETROTRANSPOSONS ARE ANCIENT COMPONENTS OF OUR GENETIC CODE THAT HAVE SELF-REPLICA | $475,000 |
| 2024 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | MOLECULAR MECHANISMS FOR SORTING LYSOSOMAL PROTEINS - PROJECT SUMMARY THE OBJECTIVE OF THIS PROPOSAL IS TO GAIN MECHANISTIC AND PATHOLOGICAL UNDERSTANDING OF HU | $460,750 |
| 2024 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | LRRK2 ENZYMATIC MECHANISMS OF NEURODEGENERATION IN PARKINSON'S DISEASE - PROJECT SUMMARY PARKINSON'S DISEASE (PD) IS A PROGRESSIVE NEURODEGENERATIVE MOVEMENT DI | $460,750 |
| 2024 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | STRUCTURAL AND FUNCTIONAL STUDIES OF CALHM CHANNELS | $459,115 |
| 2024 | National Institutes of Health | Grant or other assistance | CANCER CAUSE AND PREVENTION RESEARCH 93.393 | MECHANISMS OF CANCER MUTATIONS - PROJECT SUMMARY: CANCER GENOME SEQUENCING HAS IDENTIFIED THOUSANDS OF SOMATIC MUTATIONS IN DIFFERENT TYPES OF HUMAN CANCER. THE | $458,421 |
| 2024 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | THE STRUCTURE AND FUNCTION OF EUKARYOTIC PROTEIN GLYCOSYLATION ENZYMES | $451,250 |
| 2024 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | NETWORK AND CELLULAR VULNERABILITY TO PATHOLOGICAL PROTEIN PROGRESSION - PROJECT SUMMARY/ABSTRACT OVER 6.5 MILLION PEOPLE IN THE UNITED STATES CURRENTLY LIVE WI | $441,969 |
| 2024 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | THE CONTRIBUTION OF THE VERMIFORM APPENDIX TO PARKINSON'S DISEASE | $435,728 |
| 2024 | National Institutes of Health | Grant or other assistance | CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 | INTEGRATIVE CANCER EPIGENOMIC DATA ANALYSIS CENTER (ICE-DAC) - PROJECT SUMMARY / ABSTRACT THE WIDESPREAD NATURE OF EPIGENETIC ABNORMALITIES IN HUMAN CANCERS HA | $433,201 |
| 2024 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | EPIGENETIC CONTRIBUTIONS TO SYMPTOM ASYMMETRY IN PARKINSON'S DISEASE | $433,105 |
| 2024 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | EXPLORING MECHANISMS OF PARKINSON'S DISEASE-LINKED D620N VPS35 IN RAT MODELS | $433,105 |
| 2024 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | HIGH THROUGHPUT SCREEN FOR INHIBITORS OF THE YEATS2 HISTONE ACYLATION READER - PROJECT SUMMARY LUNG CANCER IS THE LEADING CAUSE OF CANCER-RELATED DEATHS IN BOTH | $412,895 |
| 2024 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | DISCOVERY OF SMALL MOLECULES TARGETING THE HISTONE ACETYLATION READER ENL - PROJECT SUMMARY THE MIXED-LINEAGE LEUKEMIA (MLL) GENE REARRANGEMENTS ACCOUNT FOR APP | $408,872 |
| 2024 | National Institutes of Health | Grant or other assistance | ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH 93.846 | 5-METHYLCYTOSINE OXIDATION IN DEVELOPMENT AND DISEASE - PROJECT SUMMARY: 5-METHYLCYTOSINE OXIDATION IN DEVELOPMENT AND DISEASE DNA METHYLATION AT GENE PROMOTERS | $405,460 |
| 2024 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | HIGH-THROUGHPUT EPIGENOMIC MAPPING OF REGULATORY ELEMENTS IN OVARIAN CANCER AT BASEPAIR RESOLUTION | $353,999 |
| 2024 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | DISSECTING THE ROLE OF GERMLINE GENETIC VARIATION AND VIRAL EXPOSURES AS DETERMINANTS OF HEMATOLOGICAL DISEASE PREDISPOSITION - ABSTRACT THE ROLE OF GERMLINE GE | $336,000 |
| 2024 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | MECHANISMS OF HISTONE CROSSTALK WITH BACTERIAL PATHOGENS - PROJECT SUMMARY BACTERIAL PATHOGENS MODULATE THE PHYSIOLOGY OF HUMAN CELLS BY SECRETING EFFECTOR PROT | $237,500 |
| 2024 | National Institutes of Health | Grant or other assistance | CANCER RESEARCH MANPOWER 93.398 | ONCOPROTEIN-REGULATED LINEAGE PLASTICITY IN ACUTE LEUKEMIA - ABSTRACT CHROMOSOMAL TRANSLOCATIONS INVOLVING THE LYSINE METHYLTRANSFERASE 2A (KMT2A) GENE ARE COMM | $192,240 |
| 2024 | National Institutes of Health | Grant or other assistance | CANCER CAUSE AND PREVENTION RESEARCH 93.393 | RESEARCH SPECIALIST SUPPORT-TARGETING DNA METHYLATION AND THE CANCER EPIGENOME | $166,080 |
| 2024 | National Institutes of Health | Grant or other assistance | CANCER TREATMENT RESEARCH 93.395 | UNDERSTANDING THE EFFECTS OF DIETARY INTERVENTIONS ON PANCREATIC DUCTAL ADENOCARCINOMA THERAPY CANCER - PROJECT SUMMARY/ABSTRACT PANCREATIC DUCTAL ADENOCARCINO | $160,745 |
| 2024 | National Institutes of Health | Grant or other assistance | CANCER RESEARCH MANPOWER 93.398 | THE ROLE OF AHR IN MODULATINGIMMUNOTHERAPY RESPONSE AND ADVERSE EVENTS IN BLADDER CANCER - PROJECT SUMMARY ONE HALLMARK OF CANCER IS A TUMOR’S ABILITY TO EVADE | $153,160 |
| 2024 | National Institutes of Health | Grant or other assistance | ORAL DISEASES AND DISORDERS RESEARCH 93.121 | DECIPHERING THE ROLE OF FRIZZLED RECEPTORS IN PALATAL DEVELOPMENT - PROJECT SUMMARY/ABSTRACT CLEFT LIP AND/OR CLEFT PALATE HAS AN INCIDENCE OF APPROXIMATELY 1 I | $109,274 |
| 2024 | National Science Foundation | Grant or other assistance | STEM EDUCATION (FORMERLY EDUCATION AND HUMAN RESOURCES) 47.076 | GRADUATE RESEARCH FELLOWSHIP PROGRAM (GRFP) -THE NATIONAL SCIENCE FOUNDATION (NSF) GRADUATE RESEARCH FELLOWSHIP PROGRAM (GRFP) IS A HIGHLY COMPETITIVE, FEDERAL | $53,000 |
| 2024 | National Institutes of Health | Grant or other assistance | HUMAN GENOME RESEARCH 93.172 | EPIGENOMICS WORKSHOP FOR GRADUATE STUDENTS - PROJECT SUMMARY THE FIELD OF EPIGENOMICS IS EXPANDING RAPIDLY, DRIVEN IN LARGE PART BY NEW AND EVOLVING TECHNOLOGY, | $51,777 |
| 2024 | National Institutes of Health | Grant or other assistance | CANCER CAUSE AND PREVENTION RESEARCH 93.393 | DETERMINANTS OF SUSCEPTIBILITY TO PEDIATRIC ACUTE MYELOID LEUKEMIA - F99CA294248 PI: LAUREN HARMON ADMINISTRATIVE SUPPLEMENT FOR FELLOWSHIP AWARD – CHILDCARE CO | $49,474 |
| 2024 | National Institutes of Health | Grant or other assistance | CANCER CAUSE AND PREVENTION RESEARCH 93.393 | IMPACT OF NEUROFIBROMIN ON ER-ALPHA AND NUCLEAR SPECK POST-TRANSCRIPTIONAL GENE REGULATION - PROJECT SUMMARY ALTERNATIVE SPLICING (AS) OF TRANSCRIPTS IS AN ESS | $47,974 |
| 2024 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | IDENTIFYING DETERMINANTS OF TAU PATHOLOGY SEEDING - PROJECT SUMMARY/ABSTRACT ALZHEIMER'S DISEASE (AD) IS THE MOST COMMON NEURODEGENERATIVE DISORDER IN THE UNIT | $47,974 |
| 2024 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | UPSTREAM REQUIREMENTS FOR THE REGULATION OF MITOCHONDRIAL BIOENERGETICS BY THE MITOCHONDRIAL ACYL CARRIER PROTEIN - PROJECT SUMMARY RECENT ADVANCES IN CELL BIO | $47,974 |
| 2024 | National Institutes of Health | Grant or other assistance | CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 | DETECTION OF PRE-INVASIVE PANCREATIC CYSTS USING PROTEIN AND GLYCAN BIOMARKERS | -$1,173 |
| 2024 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | ROLE OF T CELLS IN ALPHA-SYNUCLEIN PATHOLOGY - SUMMARY/ABSTRACT PARKINSON’S DISEASE (PD) IS A PROGRESSIVE NEURODEGENERATIVE DISORDER, AFFECTING OVER 1 MILLION P | -$32,608 |
| 2024 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | COMBINING SYNUCLEINOPATHY AND MITOCHONDRIAL DEFICITS IN A NOVEL MOUSE MODEL OF PARKINSONS DISEASE - THE LACK OF ANIMAL MODELS RECREATING THE PROGRESSIVE PATHOLO | -$39,099 |
| 2024 | National Institutes of Health | Grant or other assistance | CANCER RESEARCH MANPOWER 93.398 | MECHANISMS OF DNMT3B-MEDIATED DNA METHYLATION MAINTENANCE - PROJECT SUMMARY DNA METHYLATION (5MC) IS CATALYZED BY THREE DNA METHYLTRANSFERASES (DNMTS): DNMT1, D | -$39,345 |
| 2024 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | THE ROLE OF WNT SIGNALING IN NORMAL AND ABNORMAL HEMATOPOIESIS | -$96,992 |
| 2024 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | ROLE OF THE ENDOLYSOSOMAL PATHWAY IN LEWY BODY DEMENTIA - FROM POPULATION GENOMICS TO SINGLE CELLS - PROJECT SUMMARY/ABSTRACT ONE OF THE MOST COMMON ALZHEIMER’S | -$665,132 |
| 2024 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | ALZHEIMER'S DISEASE GENETIC ARCHITECTURE IN THE PORTUGUESE POPULATION | -$1,182,493 |
| 2023 | National Institutes of Health | Grant or other assistance | CANCER CAUSE AND PREVENTION RESEARCH 93.393 | TARGETING DNA METHYLATION AND THE CANCER EPIGENOME | $2,241,505 |
| 2023 | National Institutes of Health | Grant or other assistance | TRANS-NIH RESEARCH SUPPORT 93.310 | MASTER REGULATORS OF UNEXPLAINED VARIATION IN DISEASE RISK - PROJECT SUMMARY PRECISION MEDICINE REQUIRES AN UNDERSTANDING OF THE ORIGINS AND MOLECULAR CONTROL O | $1,922,580 |
| 2023 | National Institutes of Health | Grant or other assistance | TRANS-NIH RESEARCH SUPPORT 93.310 | IDENTIFYING MICROBIAL MECHANISMS THAT REGULATE ANIMAL INSULIN SIGNALING - PROJECT SUMMARY INSULIN RESISTANCE AND TYPE 2 DIABETES AFFECT NEARLY 10% OF THE POPULA | $1,710,000 |
| 2023 | Defense Health Agency | Grant or other assistance | MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 | ESTABLISHING THE NEUROPROTECTIVE POTENTIAL OF C9ORF72 HYPERMETHYLATION IN REPEAT EXPANSION-CAUSED ALS | $950,000 |
| 2023 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | CRYO-EM HIGH PERFORMANCE DATA STORAGE | $933,500 |
| 2023 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | ALZHEIMER'S DISEASE GENETIC ARCHITECTURE IN THE PORTUGUESE POPULATION | $908,823 |
| 2023 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | ACCELERATED DNA METHYLATION ALTERATIONS IN HUTCHINSON-GILFORD PROGERIA SYNDROME - PROJECT SUMMARY / ABSTRACT HUTCHINSON-GILFORD PROGERIA SYNDROME (HGPS) IS A R | $786,197 |
| 2023 | National Institutes of Health | Grant or other assistance | MENTAL HEALTH RESEARCH GRANTS 93.242 | INFLAMMATORY FACTORS AND KYNURENINE METABOLITES TRACKING SUICIDAL BEHAVIOR | $771,229 |
| 2023 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | STRUCTURAL BASIS OF NOCICEPTOR CHANNEL TRPM3 GATING AND PHARMACOLOGY - PROJECT SUMMARY THE DETECTION AND RAPID AVOIDANCE OF HARMFUL EXTERNAL STIMULI VIA PAIN PE | $770,832 |
| 2023 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | CELLULAR EPIGENETIC HETEROGENEITY AS A PREDETERMINANT OF MALIGNANT TRANSFORMATION POTENTIAL | $722,442 |
| 2023 | National Institutes of Health | Grant or other assistance | ENVIRONMENTAL HEALTH 93.113 | MOLECULAR MECHANISMS OF IAS-MEDIATED CARCINOGENESIS THROUGH THE LENS OF HISTONE H2B VARIANTS - ESTABLISHING THE INFLUENCE OF POLLUTANTS ON GENOME FUNCTION IS ES | $667,088 |
| 2023 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | KETONE BODY METABOLISM IN CD8+ T CELL RESPONSES - ABSTRACT IT HAS BEEN BELIEVED THAT INFECTION-FIGHTING T CELLS PRIMARILY USE GLUCOSE TO FUEL HOST DEFENSE AGAIN | $650,751 |
| 2023 | National Institutes of Health | Grant or other assistance | CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 | SUBPOPULATIONS OF PANCREATIC CANCER CELLS DEFINED BY GLYCAN MARKERS | $620,756 |
| 2023 | National Institutes of Health | Grant or other assistance | TRANS-NIH RESEARCH SUPPORT 93.310 | THE ROLES OF GENETICS, HORMONES, AND GENDER IN SEXUALLY DIMORPHIC IMMUNE RESPONSE - ABSTRACT SEX AND GENDER CONTRIBUTE TO THE IMMUNE SYSTEM AND HOW WE AS HUMANS | $612,008 |
| 2023 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | ENDOGENOUS RETROVIRUS IN JOINT AGING AND OSTEOARTHRITIS DEVELOPMENT - PROJECT SUMMARY/ABSTRACT OSTEOARTHRITIS (OA) IS A DEGENERATIVE DISEASE OF THE JOINTS, THAT | $607,781 |
| 2023 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | A TRIM28-ERV AXIS DRIVES PHENOTYPIC VARIATION IN OBESITY - MODIFIED PROJECT SUMMARY/ABSTRACT SECTION ESTIMATES FROM TWIN AND INBRED ANIMAL MODELS SUGGEST THAT | $600,000 |
| 2023 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | PROGRESSIVE DNA HYPOMETHYLATION AS A MEASURE OF MITOTIC HISTORY AND POTENTIAL CONTRIBUTOR TO REPLICATIVE SENESCENCE. | $597,032 |
| 2023 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | STRUCTURAL AND FUNCTIONAL STUDIES OF THE HUMAN TRPM4 AND TRPM5 CHANNELS | $579,796 |
| 2023 | National Institutes of Health | Grant or other assistance | ENVIRONMENTAL HEALTH 93.113 | MOLECULAR UNDERPINNINGS IN THE ESTABLISHMENT OF AN ONCOGENIC 3D GENOME IN RESPONSE TO ENVIRONMENTAL ARSENIC EXPOSURE | $568,959 |
| 2023 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | A NOVEL PROCESS SAFEGUARDS GENOME INTEGRITY IN THE MAMMALIAN GERM LINE - PROJECT SUMMARY SIMPLE PURINE–PYRIMIDINE (PU/PY) REPEATS (PPRS) ARE KNOWN TO FORM THE L | $531,386 |
| 2023 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | ROLE OF DESUMOYLASE SENP6 IN JOINT AGING AND OSTEOARTHRITIS DEVELOPMENT | $498,490 |
| 2023 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | TARGETED CORTICAL CIRCUIT MANIPULATION IN PARKINSON'S DISEASE - PROJECT SUMMARY/ABSTRACT THIS EXPLORATORY PROJECT IS A COLLABORATION BETWEEN PARKINSON'S DISEASE | $485,188 |
| 2023 | National Institutes of Health | Grant or other assistance | CANCER CAUSE AND PREVENTION RESEARCH 93.393 | MECHANISMS OF CANCER MUTATIONS - PROJECT SUMMARY: CANCER GENOME SEQUENCING HAS IDENTIFIED THOUSANDS OF SOMATIC MUTATIONS IN DIFFERENT TYPES OF HUMAN CANCER. THE | $482,549 |
| 2023 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | MOLECULAR MECHANISMS FOR SORTING LYSOSOMAL PROTEINS - PROJECT SUMMARY THE OBJECTIVE OF THIS PROPOSAL IS TO GAIN MECHANISTIC AND PATHOLOGICAL UNDERSTANDING OF HU | $475,000 |
| 2023 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | EPIGENETIC MECHANISMS OF RETROTRANSPOSON SILENCING - PROJECT SUMMARY/ABSTRACT RETROTRANSPOSONS ARE ANCIENT COMPONENTS OF OUR GENETIC CODE THAT HAVE SELF-REPLICA | $475,000 |
| 2023 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | UNDERSTANDING WNT9A/FZD9 TRAFFICKING AND SIGNALING - CELL TO CELL SIGNALING IS FUNDAMENTAL TO ALL MULTICELLULAR LIFE. SECRETED SIGNALING MOLECULES FROM ONE CELL | $475,000 |
| 2023 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | LRRK2 ENZYMATIC MECHANISMS OF NEURODEGENERATION IN PARKINSON'S DISEASE - PROJECT SUMMARY PARKINSON'S DISEASE (PD) IS A PROGRESSIVE NEURODEGENERATIVE MOVEMENT DI | $475,000 |
| 2023 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | ELUCIDATING STRUCTURES AND MOLECULAR MECHANISMS OF PANNEXIN CHANNELS | $475,000 |
| 2023 | National Institutes of Health | Grant or other assistance | BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 | REGULATION OF MITOCHONDRIAL FATTY ACID SYNTHESIS IN THE CONTROL OF MITOCHONDRIAL METABOLISM. - PROJECT SUMMARY LIPIDS ARE IMPORTANT CELLULAR MACROMOLECULES THA | $475,000 |
Patents
19 US patents filed in the last 20 years.
- VAN ANDEL RESEARCH INSTITUTE 19 patents, 2009-07-21 to 2025-03-04 EXACT high confidence: identical full name and state
| Patent | Title | Granted | Source |
|---|---|---|---|
| US 12240841 | FXR small molecule agonist and preparation method therefor and use thereof | 2025-03-04 | PVGPATDIS, file of 2026-04-10 |
| US 12174191 | Methods for detecting and for treating pancreatic cancer | 2024-12-24 | PVGPATDIS, file of 2026-04-10 |
| US 10954265 | Structures and mechanism for the design of highly potent glucocorticoids | 2021-03-23 | PVGPATDIS, file of 2026-04-10 |
| US 10753936 | Method of detecting the level of a glycan | 2020-08-25 | PVGPATDIS, file of 2026-04-10 |
| US 10544100 | Autophagy inhibitors | 2020-01-28 | PVGPATDIS, file of 2026-04-10 |
| US 9975918 | Highly potent glucocorticoids | 2018-05-22 | PVGPATDIS, file of 2026-04-10 |
| US 9447050 | Solid forms of curcumin | 2016-09-20 | PVGPATDIS, file of 2026-04-10 |
| US 9221760 | Autophagy inhibitors | 2015-12-29 | PVGPATDIS, file of 2026-04-10 |
| US 8632983 | Biomarkers for pancreatic cancer and diagnostic methods | 2014-01-21 | PVGPATDIS, file of 2026-04-10 |
| US 8563513 | Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use | 2013-10-22 | PVGPATDIS, file of 2026-04-10 |
The newest patents of the PatentsView assignees above, matched to this record by name (and state).
Paid as a vendor by
Other organizations that listed this one among their highest-paid independent contractors. Contractor lists give no EIN, so these are matched on name and address; check the filing.
| Year | Paid by | Service | Paid | Filing |
|---|---|---|---|---|
| 2025 | NATIONAL TUBEROUS SCLEROSIS ASSOCIATION INC | RESEARCH LAB SERVICES | $203,994 | view vendor page |
| 2024 | NATIONAL TUBEROUS SCLEROSIS ASSOCIATION INC | RESEARCH LAB SERVICES | $275,408 | view vendor page |
| 2023 | NATIONAL TUBEROUS SCLEROSIS ASSOCIATION INC | RESEARCH LAB SERVICES | $493,453 | view vendor page |
| 2021 | NATIONAL TUBEROUS SCLEROSIS ASSOCIATION INC | LABORATORY SERVICES | $227,915 | view vendor page |
| 2020 | NATIONAL TUBEROUS SCLEROSIS ASSOCIATION INC | LABORATORY SERVICES | $144,738 | view vendor page |
| 2019 | NATIONAL TUBEROUS SCLEROSIS ASSOCIATION INC | LABORATORY SERVICES | $119,005 | view vendor page |
| 2017 | NATIONAL TUBEROUS SCLEROSIS ASSOCIATION INC | RESEARCH | $133,575 | view vendor page |
Who the money went to
Grants this organization reported paying: Schedule I Part II of the Form 990, or the grants-paid list on the 990-PF. Open a year for every recipient. Recipients link to their own page when the grant names an EIN we have (990-PF grants list no EIN, so those link only on an exact, unique name and state). Grants to individuals are counted; their names are not shown.
2023 · 4 grants to organizations · $673K
Listed grants add up to $673,000; the return's “grants paid” expense line says $3,760,021. Returns can differ here (grants paid vs. accrued, items listed elsewhere); check the filing.
2022 · 4 grants to organizations · $674K
Listed grants add up to $674,500; the return's “grants paid” expense line says $2,717,278. Returns can differ here (grants paid vs. accrued, items listed elsewhere); check the filing.
2021 · 2 grants to organizations · $1.3M
Listed grants add up to $1,275,000; the return's “grants paid” expense line says $2,745,739. Returns can differ here (grants paid vs. accrued, items listed elsewhere); check the filing.
2020 · 3 grants to organizations · $640K
Listed grants add up to $640,000; the return's “grants paid” expense line says $1,630,788. Returns can differ here (grants paid vs. accrued, items listed elsewhere); check the filing.
2019 · 3 grants to organizations · $1.9M
Listed grants add up to $1,900,745; the return's “grants paid” expense line says $2,413,493. Returns can differ here (grants paid vs. accrued, items listed elsewhere); check the filing.
2018 · 2 grants to organizations · $1.5M
Listed grants add up to $1,494,431; the return's “grants paid” expense line says $2,433,098. Returns can differ here (grants paid vs. accrued, items listed elsewhere); check the filing.
2017 · 6 grants to organizations · $826K
Listed grants add up to $825,635; the return's “grants paid” expense line says $1,095,983. Returns can differ here (grants paid vs. accrued, items listed elsewhere); check the filing.
2016 · 6 grants to organizations · $607K
Listed grants add up to $607,279; the return's “grants paid” expense line says $1,012,021. Returns can differ here (grants paid vs. accrued, items listed elsewhere); check the filing.
2015 · 3 grants to organizations · $526K
Listed grants add up to $525,595; the return's “grants paid” expense line says $1,008,183. Returns can differ here (grants paid vs. accrued, items listed elsewhere); check the filing.
2014 · 3 grants to organizations · $350K
Listed grants add up to $350,000; the return's “grants paid” expense line says $764,340. Returns can differ here (grants paid vs. accrued, items listed elsewhere); check the filing.
2009 · 1 grant to organizations · $206K
Listed grants add up to $205,579; the return's “grants paid” expense line says $221,029. Returns can differ here (grants paid vs. accrued, items listed elsewhere); check the filing.
Negative amounts are returned or refunded grants; they are listed last and left out of the totals of grants paid.
Who gave
Contributor names are not public for this form type.
Public charities filing Form 990 or 990-EZ report large donors on Schedule B, but the IRS withholds their names and addresses from public copies. Private foundations (990-PF) are different: their contributors are public.
Finances
Newest first. Each filing: its name on one row, its figures on the row beneath. Greyed filings are superseded by a later return for the same period and are left out everywhere else on this page.
| Revenue | Expenses | Assets | Net assets | Contributions | Program revenue | Officer pay | Employees | Volunteers |
|---|---|---|---|---|---|---|---|---|
| 2023 · Form 990 | ||||||||
| $112,738,485 | $118,913,786 | $190,464,759 | $174,319,019 | $99,075,223 | $1,311,102 | $3,500,121 | 596 | 0 |
| 2022 · Form 990 | ||||||||
| $340,011,886 | $112,044,445 | $197,193,153 | $180,371,936 | $327,656,765 | $882,195 | $4,105,624 | 554 | 0 |
| 2021 · Form 990 | ||||||||
| $143,778,282 | $113,718,338 | $219,998,295 | -$44,512,015 | $129,397,836 | $1,224,115 | $3,744,359 | 507 | 10 |
| 2020 · Form 990 | ||||||||
| $94,830,916 | $98,445,391 | $253,165,469 | -$143,474,122 | $80,691,796 | $666,547 | $3,058,918 | 525 | 10 |
| 2019 · Form 990 | ||||||||
| $88,891,678 | $94,429,770 | $289,629,145 | -$163,865,474 | $79,336,784 | $845,797 | $3,270,696 | 525 | 12 |
| 2018 · Form 990 | ||||||||
| $86,360,028 | $99,641,728 | $274,298,502 | -$131,287,835 | $74,898,909 | $1,879,646 | $2,229,340 | 479 | 16 |
| 2017 · Form 990 | ||||||||
| $86,468,883 | $86,205,648 | $229,968,935 | -$69,943,590 | $76,050,595 | $1,206,439 | $2,283,411 | 449 | 16 |
| 2016 · Form 990 | ||||||||
| $83,066,841 | $75,551,666 | $247,321,206 | -$81,818,583 | $71,484,792 | $1,122,867 | $2,801,906 | 449 | 17 |
| 2015 · Form 990 | ||||||||
| $59,508,889 | $72,643,256 | $247,782,645 | -$96,746,386 | $50,933,876 | $1,303,818 | $2,728,257 | 424 | 0 |
| 2014 · Form 990 | ||||||||
| $65,448,267 | $69,140,666 | $250,842,142 | -$87,533,261 | $56,036,129 | $1,466,232 | $2,686,112 | 399 | 0 |
| 2013 · Form 990 | ||||||||
| $75,055,982 | $66,574,767 | $251,725,432 | -$75,972,190 | $67,009,142 | $1,460,533 | $2,384,297 | 402 | 0 |
| 2012 · Form 990 | ||||||||
| $62,599,329 | $68,033,791 | $224,789,773 | -$65,666,394 | $54,068,694 | $693,011 | $1,616,761 | 393 | 0 |
| 2011 · Form 990 | ||||||||
| $70,043,777 | $68,557,809 | $267,685,668 | -$93,416,921 | $57,997,024 | $1,242,591 | $2,248,987 | 367 | 0 |
| 2010 · Form 990 | ||||||||
| $63,688,840 | $65,553,404 | $270,167,888 | -$87,917,587 | $57,012,820 | $1,522,584 | $2,799,911 | 345 | 0 |
| 2009 · Form 990 | ||||||||
| $76,695,212 | $92,506,520 | $253,776,425 | -$58,914,192 | $69,868,505 | $1,332,729 | $3,622,793 | 248 | 0 |
Connected to
Organizations that list some of the same people on their returns (officers, directors, key employees on this organization’s latest return), and related organizations it lists on Schedule R.
- VAN ANDEL INSTITUTE Grand Rapids, MI · 5 people in common (David Van Andel, Dr Jana Hall, Gerald Callahan) · related organization (Schedule R)
- VAN ANDEL INSTITUTE GRADUATE SCHOOL Grand Rapids, MI · 5 people in common (David Van Andel, Dr James Fahner, Dr Peter Jones) · related organization (Schedule R)
- VAN ANDEL EDUCATION INSTITUTE Grand Rapids, MI · 4 people in common (David Van Andel, Gerald Callahan, Thomas Curran Jr) · related organization (Schedule R)
- FRIENDS OF CRESCENT PARK Grand Rapids, MI · 2 people in common (Dr Jana Hall, Timothy Myers)
- TRANSLATIONAL GENOMICS RESEARCH INSTITUTE Phoenix, AZ · 1 person in common (David Van Andel)
Funders of this organization
78 grantors reported grants to this organization, $569,988,755 in all, tax years 2009 to 2025; the 25 largest shown (all 78). Exact: the grantor wrote this organization's EIN. Fuzzy: the grantor wrote only a name (foundations' 990-PF has no EIN field), matched to the same or a near-identical name in the same state; the name as filed is shown. From the latest return for each grantor and year, so amended returns aren't counted twice. CSV
| Grantor | Type | Match | Years given | Grants | Total | Latest year | Latest year's amount | Grants |
|---|---|---|---|---|---|---|---|---|
| VAN ANDEL INSTITUTE | Public charity | Exact | 2019-2023 | 5 | $545,937,234 | 2023 | $61,431,822 | show |
| MICHAEL J FOX FOUNDATION FOR PARKINSONS RESEARCH | Public charity | Exact | 2011-2012, 2014-2016, 2018-2019, 2021-2022 | 12 | $2,458,850 | 2022 | $109,154 | show |
| FARMER FAMILY FOUNDATION | Private foundation | Fuzzy filed as “VAN ANDEL RESEARCH INSTITUTE” | 2020-2022 | 3 | $2,000,000 | 2022 | $500,000 | show |
| YALE UNIVERSITY | DAF sponsor | Exact | 2021-2024 | 4 | $1,620,301 | 2024 | $589,027 | show |
| ALLEN FAMILY PHILANTHROPIES | Private foundation | Fuzzy filed as “VAN ANDEL RESEARCH INSTITUTE” | 2020-2022 | 3 | $1,500,000 | 2022 | $500,000 | show |
| AMERICAN CANCER SOCIETY INC | Public charity | Exact | 2016, 2020-2021, 2023 | 4 | $1,402,390 | 2023 | $276,833 | show |
| THE MEIJER FOUNDATION | Private foundation | Fuzzy filed as “Van Andel Research Institute”, “VAN ANDEL RESEARCH INSTITUTE” | 2013-2017, 2020-2023 | 9 | $1,172,500 | 2023 | $215,000 | show |
| EMORY UNIVERSITY | Public charity | Exact | 2021-2023 | 3 | $1,162,479 | 2023 | $230,584 | show |
| UNIVERSITY OF PITTSBURGH | Public charity | Exact | 2009, 2016-2024 | 10 | $1,137,663 | 2024 | $370,978 | show |
| WASHINGTON UNIVERSITY | DAF sponsor | Exact | 2023-2024 | 2 | $1,134,602 | 2024 | $623,017 | show |
| VAN ANDEL FUND INC | Private foundation | Fuzzy filed as “VAN ANDEL RESEARCH INSTITUTE” | 2021-2022 | 2 | $1,112,698 | 2022 | $1,077,698 | show |
| CORNELL UNIVERSITY | Public charity | Exact | 2019-2024 | 6 | $868,795 | 2024 | $363,075 | show |
| FIDELITY INVESTMENTS CHARITABLE GIFT FUND | DAF sponsor | Exact | 2016-2024 | 9 | $705,947 | 2024 | $112,300 | show |
| JAY AND BETTY VAN ANDEL FOUNDATION | Private foundation | Fuzzy filed as “VAN ANDEL RESEARCH INSTITUTE” | 2020 | 1 | $667,409 | 2020 | $667,409 | show |
| AMERICAN HEART ASSOCIATION INC | Public charity | Exact | 2019, 2021, 2023 | 3 | $649,436 | 2023 | $144,580 | show |
| NORTHWESTERN UNIVERSITY | DAF sponsor | Exact | 2016-2020, 2024 | 6 | $603,812 | 2024 | $36,343 | show |
| SANDLER FOUNDATION | Public charity | Exact | 2012, 2015 | 2 | $400,000 | 2015 | $150,000 | show |
| OVARIAN CANCER RESEARCH FUND INC | Public charity | Exact | 2016-2017, 2021 | 3 | $375,000 | 2021 | $75,000 | show |
| ALEXS LEMONADE STAND FOUNDATION | Public charity | Exact | 2015-2018 | 4 | $329,386 | 2018 | $126,000 | show |
| PARKINSONS FOUNDATION INC | Public charity | Exact | 2017-2022 | 7 | $322,173 | 2022 | $40,000 | show |
| GRAND RAPIDS COMMUNITY FOUNDATION | DAF sponsor | Exact | 2010, 2014-2023 | 11 | $316,750 | 2023 | $13,250 | show |
| THE STEVE & AMY VAN ANDEL FOUNDATION | Private foundation | Fuzzy filed as “VAN ANDEL RESEARCH INSTITUTE” | 2011, 2013-2020, 2022-2024 | 19 | $288,666 | 2024 | $23,000 | show |
| THE DAVID AND CAROL VAN ANDEL FAMILY FOUNDATION | Private foundation | Fuzzy filed as “Van Andel Research Institute”, “VAN ANDEL RESEARCH INSTITUTE” | 2020-2024 | 30 | $278,680 | 2024 | $61,430 | show |
| FREY FOUNDATION | Private foundation | Fuzzy filed as “VAN ANDEL RESEARCH INSTITUTE” | 2010-2011, 2015 | 3 | $262,500 | 2015 | $2,500 | show |
| AMERICAN ASTHMA FOUNDATION | Public charity | Exact | 2011 | 1 | $250,000 | 2011 | $250,000 | show |
Similar organizations
Ranked without any AI: same NTEE code first, then the same NTEE group; then revenue within 2x, 5x or 10x; then the same state; then similar name and mission text. Same state only · More (100)
| Organization | State | NTEE | Latest revenue | Latest expenses | Top-paid title | Top pay | Why similar |
|---|---|---|---|---|---|---|---|
| INSTITUTE FOR CANCER RESEARCH | PA | H30 | $94,545,853 | $104,429,815 | Director | $2,136,271 | Same NTEE code H30, revenue within 2x, similar name |
| THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY | PA | H30 | $77,322,000 | $89,910,000 | PRESIDENT & CEO, DIRECTOR OF WISTAR CANCER CENTER | $758,347 | Same NTEE code H30, revenue within 2x |
| AMERICAN ASSOCIATION FOR CANCER RESEARCH | PA | H30 | $129,520,731 | $97,689,916 | CHIEF EXECUTIVE OFFICER | $1,705,978 | Same NTEE code H30, revenue within 2x |
| THE GOG FOUNDATION INC | MD | H30 | $92,424,680 | $82,222,187 | CFO | $384,772 | Same NTEE code H30, revenue within 2x |
| DANA FARBER MASS GENERAL BRIGHAM CANCER CARE INC | MA | H30 | $171,278,142 | $170,718,385 | FORMER OFFICER | $2,679,650 | Same NTEE code H30, revenue within 2x |
| BARBARA ANN KARMANOS CANCER INSTITUTE | MI | H30 | $27,111,385 | $33,992,462 | BOARD MEMBER | $13,036,599 | Same NTEE code H30, revenue within 5x, same state |
| BECKMAN RESEARCH INSTITUTE | CA | H30 | $332,532,052 | $385,146,731 | PRESIDENT & CEO | $7,115,860 | Same NTEE code H30, revenue within 5x, similar name |
| CANCER RESEARCH INSTITUTE INC | NY | H30 | $35,485,656 | $42,146,188 | FORMER CEO (THRU 8/2024) | $747,735 | Same NTEE code H30, revenue within 5x, similar name |
| LOUISIANA CANCER RESEARCH CENTER OF LSU HEALTH SCIENCES CENTER IN NO | LA | H30 | $25,078,516 | $23,520,798 | CAO | $255,091 | Same NTEE code H30, revenue within 5x |
| ADDGENE INC | MA | H30 | $26,391,816 | $27,557,989 | EVP/COO (Ended 10/24) | $511,427 | Same NTEE code H30, revenue within 5x |
| NRG ONCOLOGY FOUNDATION INC | PA | H30 | $35,451,240 | $35,536,029 | TREASURER | $200,003 | Same NTEE code H30, revenue within 5x |
| NSABP FOUNDATION INC | PA | H30 | $44,121,085 | $37,560,448 | CHIEF FINANCIAL OFFICER (UNTIL 4/30/25) | $324,166 | Same NTEE code H30, revenue within 5x |
| CENTRE COUNTY CANCER CENTER | PA | H30 | $43,304,913 | $45,920,267 | EXECUTIVE VP & CFO | $933,925 | Same NTEE code H30, revenue within 5x |
| CANCER RESEARCH AND BIOSTATISTICS | WA | H30 | $11,321,174 | $11,743,816 | PRESIDENT AND CEO | $464,367 | Same NTEE code H30, revenue within 10x |
| MARY CROWLEY MEDICAL RESEARCH CENTER | TX | H30 | $20,603,348 | $17,107,470 | EXECUTIVE MEDICAL DIRECTOR | $732,089 | Same NTEE code H30, revenue within 10x |
| COUNT ME IN INC | MA | H30 | $11,767,611 | $5,257,373 | Director/President (unt 12/22) | $181,768 | Same NTEE code H30, revenue within 10x |
| ULTA BEAUTY CHARITABLE FOUNDATION | IL | H30 | $11,854,534 | $12,890,343 | President | $0 | Same NTEE code H30, revenue within 10x |
| CHORDOMA FOUNDATION | NC | H30 | $13,413,691 | $6,132,279 | HEAD OF PHILANTHROPY | $243,190 | Same NTEE code H30, revenue within 10x |
| INTERNATIONAL MYELOMA SOCIETY | H30 | $11,815,468 | $9,724,228 | Secretary | $0 | Same NTEE code H30, revenue within 10x | |
| HEALTH RESEARCH INCORPORATED ELIZABETH WOOD | NY | H30 | $912,790,717 | $1,001,279,801 | Assistant Director, Cytogenetics | $306,977 | Same NTEE code H30, revenue within 10x |
| PEACH PHILANTHROPIC ENDOWMENT ADVANCING CHILDRENS HEALTH INC | MI | H30 | $199,112 | $36,904 | President | $0 | Same NTEE code H30, revenue differs more than 10x, same state |
| ANNIS ARMY FOUNDATION | MI | H30 | $62,749 | $61,907 | President | $0 | Same NTEE code H30, revenue differs more than 10x, same state |
| CHILDRENS CANCER AID AND RESEARCH INSTITUTE | AZ | H30 | $68,327 | $66,904 | PRESIDENT | $28,020 | Same NTEE code H30, revenue differs more than 10x, similar name |
| PROSTATE CANCER RESEARCH INSTITUTE | CA | H30 | $1,630,544 | $1,255,954 | KEY EMPLOYEE | $174,250 | Same NTEE code H30, revenue differs more than 10x, similar name |
| ELLISON INSTITUTE RESEARCH FOUNDATION | CA | H30 | $2,134,752 | $1,081,731 | DIRECTOR/PRESIDENT | $0 | Same NTEE code H30, revenue differs more than 10x, similar name |
Who funds organizations like this
Grantors that funded the 100 most similar organizations. Ranked by total given to them. Foundations (990-PF) and donor-advised fund sponsors only. Same matching as Funders above (by EIN, or by name for foundations).
The full list · all similar organizations
Where the money went
Every expense line on each return, biggest first: Form 990 Part IX (with its program, management and fundraising columns), 990-EZ Part I, or 990-PF Part I. Event marks lines the organization itself describes as events. “Events” in each summary adds those lines, conferences and meetings, and the direct costs of fundraising events. Unusual is not the same as improper. Many of these patterns have ordinary explanations. Check the filing.
2023 · Form 990 · $118,913,786 spent · pay $67,657,719 · grants $3,760,021 · events $619,797
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $51,545,057 | $31,210,574 | $19,072,394 | $1,262,089 | 43.3% | |
| Depreciation and depletion | $13,665,696 | $11,999,973 | $1,665,723 | - | 11.5% | |
| Other (as described) | LAB SUPPLIES & SERVICES | $7,464,454 | $7,463,658 | $796 | - | 6.3% |
| Other (as described) | EQUIPMENT & SOFTWARE | $5,903,439 | $3,395,467 | $2,500,518 | $7,454 | 5.0% |
| Other employee benefits | $4,869,110 | $2,952,347 | $1,780,611 | $136,152 | 4.1% | |
| All other expenses | $4,409,025 | $2,254,157 | $2,089,339 | $65,529 | 3.7% | |
| Fees: other services | $4,406,771 | $2,718,601 | $1,688,170 | - | 3.7% | |
| Pension plan contributions | $4,328,910 | $2,624,801 | $1,583,062 | $121,047 | 3.6% | |
| Pay: officers, directors, trustees, key employees | $3,500,121 | $871,533 | $2,628,588 | - | 2.9% | |
| Payroll taxes | $3,414,521 | $2,070,369 | $1,248,674 | $95,478 | 2.9% | |
| Occupancy | $2,921,054 | $2,491,213 | $429,841 | - | 2.5% | |
| Advertising and promotion | $2,796,447 | $70,378 | $2,434,413 | $291,656 | 2.4% | |
| Grants to US individuals | $2,297,021 | $2,297,021 | - | - | 1.9% | |
| Other (as described) | OTHER SCIENTIFIC | $1,509,022 | $1,509,022 | - | - | 1.3% |
| Travel | $1,353,322 | $1,020,312 | $307,965 | $25,045 | 1.1% | |
| Insurance | $1,029,810 | $638,482 | $391,328 | - | 0.9% | |
| Grants outside the US | $790,000 | $790,000 | - | - | 0.7% | |
| Information technology | $709,593 | $121,058 | $558,153 | $30,382 | 0.6% | |
| Grants to US organizations and governments | $673,000 | $673,000 | - | - | 0.6% | |
| Conferences, conventions and meetings | $525,502 | $437,030 | $85,438 | $3,034 | 0.4% | |
| Fees: legal | $458,292 | $77,271 | $381,021 | - | 0.4% | |
| Fees: accounting | $133,335 | - | $133,335 | - | 0.1% | |
| Fees: lobbying | $96,000 | - | $96,000 | - | 0.1% | |
| Other (as described) | FED / STATE INCOME TAX | $58,721 | - | $57,096 | $1,625 | 0.0% |
| Office expenses | $27,121 | $1,734 | $25,100 | $287 | 0.0% | |
| Royalties | $16,613 | - | $16,613 | - | 0.0% | |
| Interest | $11,829 | $5,548 | $6,281 | - | 0.0% | |
| Fundraising events Event | direct expenses; gross income $153,234 | $94,295 | reported apart | |||
| Total | $118,913,786 | 100% |
2022 · Form 990 · $112,044,445 spent · pay $63,920,211 · grants $2,717,278 · events $679,157
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $47,005,351 | $29,152,344 | $17,462,161 | $390,846 | 42.0% | |
| Depreciation and depletion | $12,375,602 | $11,046,989 | $1,328,613 | - | 11.0% | |
| Other (as described) | LAB SUPPLIES & SERVICES | $7,287,526 | $7,287,526 | - | - | 6.5% |
| Other (as described) | EQUIPMENT & SOFTWARE | $5,757,192 | $3,184,915 | $2,568,894 | $3,383 | 5.1% |
| Other employee benefits | $5,241,166 | $3,391,661 | $1,807,191 | $42,314 | 4.7% | |
| Pension plan contributions | $4,293,326 | $2,778,295 | $1,480,369 | $34,662 | 3.8% | |
| Fees: other services | $4,267,604 | $2,406,149 | $1,860,652 | $803 | 3.8% | |
| Pay: officers, directors, trustees, key employees | $4,105,624 | $997,060 | $3,108,564 | - | 3.7% | |
| All other expenses | $4,038,010 | $1,766,915 | $2,203,250 | $67,845 | 3.6% | |
| Payroll taxes | $3,274,744 | $2,119,151 | $1,129,155 | $26,438 | 2.9% | |
| Occupancy | $2,728,122 | $2,257,577 | $470,545 | - | 2.4% | |
| Advertising and promotion | $2,254,456 | $30,959 | $2,051,413 | $172,084 | 2.0% | |
| Grants to US individuals | $2,022,778 | $2,022,778 | - | - | 1.8% | |
| Other (as described) | OTHER SCIENTIFIC | $1,503,784 | $1,503,784 | - | - | 1.3% |
| Interest | $1,317,022 | $1,079,988 | $237,034 | - | 1.2% | |
| Travel | $1,298,951 | $937,105 | $314,367 | $47,479 | 1.2% | |
| Insurance | $907,545 | $571,252 | $336,293 | - | 0.8% | |
| Grants to US organizations and governments | $689,500 | $689,500 | - | - | 0.6% | |
| Fees: legal | $561,645 | $141,393 | $420,252 | - | 0.5% | |
| Conferences, conventions and meetings | $501,955 | $409,058 | $87,824 | $5,073 | 0.4% | |
| Information technology | $384,055 | $125,892 | $244,837 | $13,326 | 0.3% | |
| Fees: lobbying | $96,000 | - | $96,000 | - | 0.1% | |
| Office expenses | $65,378 | $22,483 | $38,685 | $4,210 | 0.1% | |
| Fees: accounting | $61,683 | - | $61,683 | - | 0.1% | |
| Grants outside the US | $5,000 | $5,000 | - | - | 0.0% | |
| Other (as described) | FED / STATE INCOME TAX | $426 | - | $426 | - | 0.0% |
| Fundraising events Event | direct expenses; gross income $76,289 | $177,202 | reported apart | |||
| Total | $112,044,445 | 100% |
2021 · Form 990 · $113,718,338 spent · pay $57,365,730 · grants $2,745,739 · events $531,622
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $42,761,181 | $27,807,380 | $14,507,038 | $446,763 | 37.6% | |
| Depreciation and depletion | $11,467,262 | $9,763,636 | $1,703,626 | - | 10.1% | |
| Interest | $8,772,118 | $6,778,411 | $1,993,707 | - | 7.7% | |
| Other (as described) | LAB SUPPLIES & SERVICES | $8,562,063 | $8,562,063 | - | - | 7.5% |
| All other expenses | $4,747,156 | $3,469,088 | $1,215,195 | $62,873 | 4.2% | |
| Other (as described) | EQUIPMENT & SOFTWARE | $4,708,813 | $2,858,217 | $1,848,282 | $2,314 | 4.1% |
| Other employee benefits | $4,384,199 | $2,658,649 | $1,683,938 | $41,612 | 3.9% | |
| Fees: other services | $4,194,312 | $2,713,800 | $1,480,512 | - | 3.7% | |
| Pay: officers, directors, trustees, key employees | $3,744,359 | $971,390 | $2,772,969 | - | 3.3% | |
| Pension plan contributions | $3,684,820 | $2,234,534 | $1,415,312 | $34,974 | 3.2% | |
| Advertising and promotion | $2,979,354 | $11,903 | $2,827,862 | $139,589 | 2.6% | |
| Payroll taxes | $2,791,171 | $1,692,611 | $1,072,068 | $26,492 | 2.5% | |
| Occupancy | $2,639,110 | $2,051,054 | $588,056 | - | 2.3% | |
| Other (as described) | OTHER SCIENTIFIC | $1,897,957 | $1,897,957 | - | - | 1.7% |
| Grants to US individuals | $1,465,739 | $1,465,739 | - | - | 1.3% | |
| Grants to US organizations and governments | $1,280,000 | $1,280,000 | - | - | 1.1% | |
| Insurance | $885,713 | $433,968 | $451,745 | - | 0.8% | |
| Travel | $738,225 | $502,290 | $192,326 | $43,609 | 0.6% | |
| Fees: legal | $681,245 | $128,764 | $552,481 | - | 0.6% | |
| Information technology | $495,469 | $156,591 | $328,146 | $10,732 | 0.4% | |
| Conferences, conventions and meetings | $404,685 | $348,150 | $56,535 | - | 0.4% | |
| Office expenses | $191,722 | $61,274 | $119,887 | $10,561 | 0.2% | |
| Fees: accounting | $104,322 | $13,000 | $91,322 | - | 0.1% | |
| Fees: lobbying | $96,000 | - | $96,000 | - | 0.1% | |
| Other (as described) | FED / STATE INCOME TAX | $41,343 | - | $41,343 | - | 0.0% |
| Fundraising events Event | direct expenses; gross income $87,423 | $126,937 | reported apart | |||
| Total | $113,718,338 | 100% |
2020 · Form 990 · $98,445,391 spent · pay $50,445,397 · grants $1,630,788 · events $145,702
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $38,413,594 | $24,648,126 | $13,301,120 | $464,348 | 39.0% | |
| Depreciation and depletion | $11,726,239 | $9,957,488 | $1,768,751 | - | 11.9% | |
| Interest | $8,932,677 | $6,896,008 | $2,036,669 | - | 9.1% | |
| Other (as described) | LAB SUPPLIES & SERVICES | $6,169,608 | $6,169,608 | - | - | 6.3% |
| Other (as described) | EQUIPMENT & SOFTWARE | $4,816,151 | $2,604,890 | $2,210,965 | $296 | 4.9% |
| All other expenses | $3,728,195 | $1,867,373 | $1,847,553 | $13,269 | 3.8% | |
| Other employee benefits | $3,628,983 | $2,203,619 | $1,375,688 | $49,676 | 3.7% | |
| Fees: other services | $3,525,117 | $2,487,774 | $1,037,343 | - | 3.6% | |
| Pension plan contributions | $3,278,142 | $1,990,579 | $1,242,690 | $44,873 | 3.3% | |
| Pay: officers, directors, trustees, key employees | $3,058,918 | $777,432 | $2,281,486 | - | 3.1% | |
| Occupancy | $2,468,639 | $1,937,015 | $531,616 | $8 | 2.5% | |
| Payroll taxes | $2,065,760 | $1,254,387 | $783,096 | $28,277 | 2.1% | |
| Advertising and promotion | $1,359,316 | $5,940 | $1,233,869 | $119,507 | 1.4% | |
| Grants to US individuals | $990,788 | $990,788 | - | - | 1.0% | |
| Other (as described) | OTHER SCIENTIFIC | $924,286 | $924,286 | - | - | 0.9% |
| Insurance | $763,313 | $375,198 | $388,115 | - | 0.8% | |
| Fees: legal | $729,430 | $94,645 | $634,785 | - | 0.7% | |
| Grants to US organizations and governments | $640,000 | $640,000 | - | - | 0.7% | |
| Information technology | $564,260 | $158,859 | $310,540 | $94,861 | 0.6% | |
| Fees: accounting | $181,452 | - | $181,452 | - | 0.2% | |
| Office expenses | $164,104 | $34,375 | $128,431 | $1,298 | 0.2% | |
| Travel | $106,946 | $64,998 | $33,843 | $8,105 | 0.1% | |
| Fees: lobbying | $96,000 | - | $96,000 | - | 0.1% | |
| Conferences, conventions and meetings | $92,551 | $50,081 | $42,470 | - | 0.1% | |
| Other (as described) | FED / STATE INCOME TAX | $20,922 | - | $20,922 | - | 0.0% |
| Fundraising events Event | direct expenses; gross income $1,235 | $53,151 | reported apart | |||
| Total | $98,445,391 | 100% |
2019 · Form 990 · $94,429,770 spent · pay $47,981,506 · grants $2,413,493 · events $137,564
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $35,488,373 | $23,593,456 | $11,415,396 | $479,521 | 37.6% | |
| Depreciation and depletion | $11,763,681 | $10,030,415 | $1,733,266 | - | 12.5% | |
| Interest | $8,726,165 | $6,699,249 | $2,026,916 | - | 9.2% | |
| Other (as described) | LAB SUPPLIES & SERVICES | $5,029,175 | $5,029,175 | - | - | 5.3% |
| Fees: other services | $4,276,977 | $2,962,202 | $1,304,562 | $10,213 | 4.5% | |
| Other (as described) | EQUIPMENT & SOFTWARE | $4,015,146 | $2,279,055 | $1,734,692 | $1,399 | 4.3% |
| Other employee benefits | $3,956,520 | $2,644,467 | $1,262,143 | $49,910 | 4.2% | |
| Pay: officers, directors, trustees, key employees | $3,270,696 | $873,582 | $2,397,114 | - | 3.5% | |
| Pension plan contributions | $2,945,386 | $1,968,643 | $939,588 | $37,155 | 3.1% | |
| Occupancy | $2,537,460 | $1,977,941 | $559,361 | $158 | 2.7% | |
| All other expenses | $2,394,185 | $1,076,513 | $1,308,506 | $9,166 | 2.5% | |
| Payroll taxes | $2,320,531 | $1,551,001 | $740,257 | $29,273 | 2.5% | |
| Grants to US organizations and governments | $1,900,745 | $1,900,745 | - | - | 2.0% | |
| Fees: legal | $1,556,708 | $85,382 | $1,471,326 | - | 1.6% | |
| Other (as described) | OTHER SCIENTIFIC | $982,042 | $982,042 | - | - | 1.0% |
| Advertising and promotion | $981,123 | $4,694 | $851,686 | $124,743 | 1.0% | |
| Insurance | $630,655 | $314,944 | $315,711 | - | 0.7% | |
| Grants to US individuals | $512,748 | $512,748 | - | - | 0.5% | |
| Information technology | $376,019 | $153,140 | $197,754 | $25,125 | 0.4% | |
| Travel | $219,340 | $123,562 | $80,134 | $15,644 | 0.2% | |
| Office expenses | $196,114 | $33,411 | $162,590 | $113 | 0.2% | |
| Fees: accounting | $128,809 | - | $128,809 | - | 0.1% | |
| Fees: lobbying | $96,000 | - | $96,000 | - | 0.1% | |
| Conferences, conventions and meetings | $80,578 | $44,778 | $35,800 | - | 0.1% | |
| Other (as described) | FED / STATE INCOME TAX | $44,223 | - | $44,223 | - | 0.0% |
| Royalties | $371 | - | $371 | - | 0.0% | |
| Fundraising events Event | direct expenses; gross income $7,712 | $56,986 | reported apart | |||
| Total | $94,429,770 | 100% |
2018 · Form 990 · $99,641,728 spent · pay $45,621,394 · grants $2,433,098 · events $429,484
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $34,562,207 | $22,300,073 | $11,564,759 | $697,375 | 34.7% | |
| Depreciation and depletion | $11,429,828 | $9,856,751 | $1,573,077 | - | 11.5% | |
| Interest | $8,876,844 | $6,906,334 | $1,970,510 | - | 8.9% | |
| Other (as described) | LAB SUPPLIES & SERVICES | $6,389,206 | $6,389,206 | - | - | 6.4% |
| Other (as described) | MISCELLANEOUS | $5,820,901 | $39,610 | $5,768,173 | $13,118 | 5.8% |
| All other expenses | $4,886,184 | $3,415,543 | $1,467,172 | $3,469 | 4.9% | |
| Other (as described) | EQUIPMENT & SOFTWARE | $3,903,931 | $2,386,071 | $1,516,635 | $1,225 | 3.9% |
| Other employee benefits | $3,817,031 | $2,444,193 | $1,321,476 | $51,362 | 3.8% | |
| Fees: other services | $2,963,605 | $2,074,204 | $883,036 | $6,365 | 3.0% | |
| Pension plan contributions | $2,894,775 | $1,842,351 | $995,005 | $57,419 | 2.9% | |
| Occupancy | $2,743,128 | $2,108,470 | $632,558 | $2,100 | 2.8% | |
| Pay: officers, directors, trustees, key employees | $2,229,340 | $767,220 | $1,462,120 | - | 2.2% | |
| Payroll taxes | $2,118,041 | $1,333,127 | $718,552 | $66,362 | 2.1% | |
| Grants to US organizations and governments | $1,494,431 | $1,494,431 | - | - | 1.5% | |
| Fees: legal | $1,107,317 | $83,553 | $1,023,764 | - | 1.1% | |
| Grants to US individuals | $938,667 | $938,667 | - | - | 0.9% | |
| Travel | $890,566 | $627,192 | $229,258 | $34,116 | 0.9% | |
| Advertising and promotion | $853,085 | $384 | $717,261 | $135,440 | 0.9% | |
| Insurance | $548,635 | $347,815 | $200,820 | - | 0.6% | |
| Conferences, conventions and meetings | $370,209 | $287,106 | $77,827 | $5,276 | 0.4% | |
| Information technology | $326,053 | $140,901 | $176,641 | $8,511 | 0.3% | |
| Office expenses | $174,360 | $50,800 | $123,486 | $74 | 0.2% | |
| Fees: lobbying | $96,000 | - | $96,000 | - | 0.1% | |
| Royalties | $78,255 | - | $78,255 | - | 0.1% | |
| Fees: accounting | $72,791 | - | $72,791 | - | 0.1% | |
| Other (as described) | FED / STATE INCOME TAX | $56,338 | - | $56,338 | - | 0.1% |
| Fundraising events Event | direct expenses; gross income $10,260 | $59,275 | reported apart | |||
| Total | $99,641,728 | 100% |
2017 · Form 990 · $86,205,648 spent · pay $39,942,174 · grants $1,095,983 · events $204,458
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $29,071,924 | $17,890,164 | $10,590,249 | $591,511 | 33.7% | |
| Depreciation and depletion | $10,976,842 | $9,408,576 | $1,568,266 | - | 12.7% | |
| Interest | $10,760,495 | $7,999,832 | $2,760,663 | - | 12.5% | |
| Other (as described) | LAB SUPPLIES & SERVICES | $5,162,377 | $5,162,377 | - | - | 6.0% |
| All other expenses | $4,485,751 | $3,664,306 | $805,746 | $15,699 | 5.2% | |
| Other employee benefits | $4,044,566 | $2,411,691 | $1,557,985 | $74,890 | 4.7% | |
| Other (as described) | EQUIPMENT & SOFTWARE | $3,794,364 | $2,762,597 | $1,030,455 | $1,312 | 4.4% |
| Pension plan contributions | $2,661,929 | $1,587,253 | $1,025,387 | $49,289 | 3.1% | |
| Occupancy | $2,604,067 | $2,067,187 | $535,615 | $1,265 | 3.0% | |
| Fees: other services | $2,337,221 | $1,801,631 | $514,677 | $20,913 | 2.7% | |
| Pay: officers, directors, trustees, key employees | $2,283,411 | $806,925 | $1,476,486 | - | 2.6% | |
| Payroll taxes | $1,880,344 | $1,121,210 | $724,317 | $34,817 | 2.2% | |
| Other (as described) | BAD DEBT EXPENSE (ADJUS | $1,572,658 | - | $1,572,658 | - | 1.8% |
| Grants to US organizations and governments | $827,751 | $827,751 | - | - | 1.0% | |
| Advertising and promotion | $760,537 | $29,289 | $586,536 | $144,712 | 0.9% | |
| Travel | $743,796 | $520,941 | $200,269 | $22,586 | 0.9% | |
| Insurance | $533,115 | $333,064 | $200,051 | - | 0.6% | |
| Fees: legal | $460,633 | $45,459 | $415,174 | - | 0.5% | |
| Information technology | $340,238 | $162,710 | $172,387 | $5,141 | 0.4% | |
| Grants to US individuals | $217,006 | $217,006 | - | - | 0.3% | |
| Conferences, conventions and meetings | $182,155 | $113,331 | $63,337 | $5,487 | 0.2% | |
| Office expenses | $150,365 | $54,671 | $95,634 | $60 | 0.2% | |
| Other (as described) | FED / STATE INCOME TAX | $135,824 | $0 | $135,824 | - | 0.2% |
| Fees: lobbying | $96,000 | - | $96,000 | - | 0.1% | |
| Fees: accounting | $71,053 | - | $71,053 | - | 0.1% | |
| Grants outside the US | $51,226 | $51,226 | - | - | 0.1% | |
| Fundraising events Event | direct expenses; gross income $7,940 | $22,303 | reported apart | |||
| Total | $86,205,648 | 100% |
2016 · Form 990 · $75,551,666 spent · pay $36,040,459 · grants $1,012,021 · events $291,625
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $27,698,120 | $16,972,685 | $10,165,866 | $559,569 | 36.7% | |
| Depreciation and depletion | $9,857,047 | $8,564,010 | $1,293,037 | - | 13.0% | |
| Interest | $8,935,202 | $7,464,402 | $1,470,800 | - | 11.8% | |
| Other (as described) | LAB SUPPLIES & SERVICES | $4,361,004 | $4,361,004 | - | - | 5.8% |
| Other (as described) | EQUIPMENT & SOFTWARE | $3,114,129 | $1,678,024 | $1,435,082 | $1,023 | 4.1% |
| Pay: officers, directors, trustees, key employees | $2,801,906 | $1,079,504 | $1,722,402 | - | 3.7% | |
| Occupancy | $2,335,871 | $2,153,298 | $182,041 | $532 | 3.1% | |
| Fees: other services | $2,285,220 | $1,919,127 | $359,843 | $6,250 | 3.0% | |
| Pension plan contributions | $2,217,789 | $1,316,417 | $841,369 | $60,003 | 2.9% | |
| All other expenses | $2,176,288 | $1,191,257 | $979,827 | $5,204 | 2.9% | |
| Payroll taxes | $1,812,981 | $1,076,384 | $688,596 | $48,001 | 2.4% | |
| Other employee benefits | $1,509,663 | $908,098 | $559,563 | $42,002 | 2.0% | |
| Other (as described) | CLINICAL TRIAL COST | $1,258,125 | $1,258,125 | - | - | 1.7% |
| Other (as described) | OTHER SCIENTIFIC | $1,016,840 | $1,016,840 | - | - | 1.3% |
| Travel | $717,382 | $487,725 | $217,538 | $12,119 | 0.9% | |
| Advertising and promotion | $716,949 | $3,593 | $598,356 | $115,000 | 0.9% | |
| Grants to US organizations and governments | $609,014 | $609,014 | - | - | 0.8% | |
| Insurance | $537,287 | $342,428 | $194,859 | - | 0.7% | |
| Fees: legal | $296,531 | $35,364 | $261,167 | - | 0.4% | |
| Information technology | $280,909 | $110,214 | $170,695 | - | 0.4% | |
| Conferences, conventions and meetings | $272,625 | $213,030 | $58,621 | $974 | 0.4% | |
| Grants to US individuals | $258,471 | $258,471 | - | - | 0.3% | |
| Office expenses | $158,259 | $53,465 | $104,789 | $5 | 0.2% | |
| Grants outside the US | $144,536 | $144,536 | - | - | 0.2% | |
| Fees: lobbying | $96,000 | - | $96,000 | - | 0.1% | |
| Fees: accounting | $83,518 | - | $83,518 | - | 0.1% | |
| Fundraising events Event | direct expenses; gross income $8,385 | $19,000 | reported apart | |||
| Total | $75,551,666 | 100% |
2015 · Form 990 · $72,643,256 spent · pay $35,314,051 · grants $1,008,183 · events $257,475
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $25,889,699 | $15,912,072 | $9,443,070 | $534,557 | 35.6% | |
| Depreciation and depletion | $9,688,993 | $8,333,054 | $1,355,939 | - | 13.3% | |
| Interest | $8,721,337 | $7,263,246 | $1,458,091 | - | 12.0% | |
| Other (as described) | LAB SUPPLIES & SERVICES | $3,546,204 | $3,546,204 | - | - | 4.9% |
| Other employee benefits | $3,058,443 | $1,835,144 | $1,152,883 | $70,416 | 4.2% | |
| Other (as described) | EQUIPMENT & SOFTWARE | $2,896,321 | $1,499,921 | $1,389,252 | $7,148 | 4.0% |
| Pay: officers, directors, trustees, key employees | $2,728,257 | $1,058,584 | $1,669,673 | - | 3.8% | |
| Fees: other services | $2,432,065 | $2,077,025 | $350,277 | $4,763 | 3.3% | |
| Occupancy | $2,397,521 | $2,186,723 | $209,847 | $951 | 3.3% | |
| Pension plan contributions | $2,000,471 | $1,200,333 | $754,214 | $45,924 | 2.8% | |
| All other expenses | $1,826,060 | $540,438 | $1,279,353 | $6,269 | 2.5% | |
| Payroll taxes | $1,637,181 | $982,349 | $618,093 | $36,739 | 2.3% | |
| Other (as described) | OTHER SCIENTIFIC | $1,200,387 | $1,200,387 | - | - | 1.7% |
| Advertising and promotion | $676,578 | $58,708 | $543,136 | $74,734 | 0.9% | |
| Travel | $644,792 | $429,145 | $205,200 | $10,447 | 0.9% | |
| Other (as described) | ALLOCATED EXPENSES | $566,458 | $560,189 | - | $6,269 | 0.8% |
| Grants to US organizations and governments | $526,007 | $526,007 | - | - | 0.7% | |
| Fees: legal | $477,838 | $46,987 | $430,851 | - | 0.7% | |
| Insurance | $447,507 | $275,622 | $171,885 | - | 0.6% | |
| Grants to US individuals | $328,146 | $328,146 | - | - | 0.5% | |
| Information technology | $270,677 | $125,142 | $145,343 | $192 | 0.4% | |
| Conferences, conventions and meetings | $235,222 | $180,453 | $52,921 | $1,848 | 0.3% | |
| Grants outside the US | $154,030 | $154,030 | - | - | 0.2% | |
| Fees: lobbying | $124,034 | - | $124,034 | - | 0.2% | |
| Office expenses | $97,220 | $56,675 | $40,487 | $58 | 0.1% | |
| Fees: accounting | $71,808 | - | $71,808 | - | 0.1% | |
| Fundraising events Event | direct expenses; gross income $9,860 | $22,253 | reported apart | |||
| Total | $72,643,256 | 100% |
2014 · Form 990 · $69,140,666 spent · pay $32,131,259 · grants $764,340 · events $271,513
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $23,149,989 | $13,725,800 | $8,657,351 | $766,838 | 33.5% | |
| Depreciation and depletion | $9,304,114 | $7,999,395 | $1,304,719 | - | 13.5% | |
| Interest | $8,630,838 | $7,180,473 | $1,450,365 | - | 12.5% | |
| Other (as described) | LAB SUPPLIES & SERVICES | $3,636,360 | $3,614,210 | $22,150 | $0 | 5.3% |
| Other employee benefits | $3,014,640 | $1,804,565 | $1,130,924 | $79,151 | 4.4% | |
| Fees: other services | $2,839,850 | $2,331,875 | $499,790 | $8,185 | 4.1% | |
| Other (as described) | EQUIPMENT & SOFTWARE | $2,753,651 | $1,320,986 | $1,426,318 | $6,347 | 4.0% |
| Pay: officers, directors, trustees, key employees | $2,686,112 | $1,061,907 | $1,624,205 | - | 3.9% | |
| Occupancy | $2,224,334 | $1,971,415 | $251,199 | $1,720 | 3.2% | |
| All other expenses | $2,216,835 | $1,156,670 | $1,038,460 | $21,705 | 3.2% | |
| Pension plan contributions | $1,683,543 | $1,007,752 | $631,268 | $44,523 | 2.4% | |
| Payroll taxes | $1,596,975 | $955,987 | $599,763 | $41,225 | 2.3% | |
| Advertising and promotion | $1,002,668 | $81,114 | $843,854 | $77,700 | 1.5% | |
| Travel | $761,554 | $389,266 | $358,539 | $13,749 | 1.1% | |
| Other (as described) | BAD DEBT EXPENSE | $614,600 | $0 | $614,600 | $0 | 0.9% |
| Other (as described) | ALLOCATED EXPENSES | $550,593 | $550,593 | $0 | $0 | 0.8% |
| Insurance | $471,162 | $286,218 | $184,944 | - | 0.7% | |
| Fees: legal | $444,805 | $47,991 | $396,814 | - | 0.6% | |
| Grants to US organizations and governments | $352,667 | $352,667 | - | - | 0.5% | |
| Conferences, conventions and meetings | $263,443 | $209,003 | $54,440 | - | 0.4% | |
| Grants to US individuals | $261,494 | $261,494 | - | - | 0.4% | |
| Information technology | $257,773 | $119,336 | $133,361 | $5,076 | 0.4% | |
| Grants outside the US | $150,179 | $150,179 | - | - | 0.2% | |
| Fees: accounting | $128,300 | - | $128,300 | - | 0.2% | |
| Office expenses | $98,687 | $55,224 | $43,130 | $333 | 0.1% | |
| Fees: lobbying | $45,500 | - | $45,500 | - | 0.1% | |
| Fundraising events Event | direct expenses; gross income $0 | $8,070 | reported apart | |||
| Total | $69,140,666 | 100% |
2013 · Form 990 · $66,574,767 spent · pay $29,232,885 · grants $201,907 · events $195,902
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $21,012,535 | $11,883,978 | $8,420,804 | $707,753 | 31.6% | |
| Depreciation and depletion | $9,128,908 | $7,880,962 | $1,247,946 | - | 13.7% | |
| Interest | $8,633,669 | $7,182,829 | $1,450,840 | - | 13.0% | |
| Other (as described) | LAB SUPPLIES & SERVICES | $3,223,883 | $3,214,501 | $9,382 | - | 4.8% |
| Other employee benefits | $2,903,422 | $1,751,315 | $1,061,301 | $90,806 | 4.4% | |
| Fees: other services | $2,711,964 | $2,024,936 | $558,301 | $128,727 | 4.1% | |
| Other (as described) | EQUIPMENT & SOFTWARE | $2,607,673 | $1,276,892 | $1,312,073 | $18,708 | 3.9% |
| All other expenses | $2,522,872 | $1,431,933 | $1,027,827 | $63,112 | 3.8% | |
| Occupancy | $2,511,541 | $2,235,158 | $274,077 | $2,306 | 3.8% | |
| Pay: officers, directors, trustees, key employees | $2,384,297 | $769,206 | $1,615,091 | - | 3.6% | |
| Pension plan contributions | $1,716,490 | $1,035,265 | $628,557 | $52,668 | 2.6% | |
| Other (as described) | OTHER SCIENTIFIC | $1,303,572 | $1,295,845 | $7,727 | - | 2.0% |
| Advertising and promotion | $1,226,668 | $4,637 | $1,079,977 | $142,054 | 1.8% | |
| Payroll taxes | $1,216,141 | $733,574 | $444,428 | $38,139 | 1.8% | |
| Travel | $875,355 | $436,370 | $387,963 | $51,022 | 1.3% | |
| Other (as described) | BAD DEBT EXPENSE | $523,400 | - | $523,400 | - | 0.8% |
| Insurance | $438,396 | $268,277 | $170,119 | - | 0.7% | |
| Fees: legal | $407,217 | $63,881 | $343,336 | - | 0.6% | |
| Information technology | $361,357 | $142,065 | $203,435 | $15,857 | 0.5% | |
| Fees: lobbying | $262,848 | - | $262,848 | - | 0.4% | |
| Grants to US individuals | $201,907 | $201,907 | - | - | 0.3% | |
| Conferences, conventions and meetings | $195,902 | $133,428 | $59,489 | $2,985 | 0.3% | |
| Fees: accounting | $105,100 | - | $105,100 | - | 0.2% | |
| Office expenses | $99,650 | $49,654 | $49,689 | $307 | 0.1% | |
| Total | $66,574,767 | 100% |
2012 · Form 990 · $68,033,791 spent · pay $28,311,621 · grants $302,224 · events $165,374
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $20,778,216 | $11,714,526 | $8,670,213 | $393,477 | 30.5% | |
| Interest | $10,523,660 | $8,634,262 | $1,889,398 | - | 15.5% | |
| Depreciation and depletion | $9,314,843 | $7,879,994 | $1,434,849 | - | 13.7% | |
| Other (as described) | LAB SUPPLIES & SERVICES | $3,083,328 | $3,074,127 | $9,201 | - | 4.5% |
| Fees: other services | $2,670,755 | $1,807,905 | $862,212 | $638 | 3.9% | |
| Other employee benefits | $2,635,984 | $1,592,869 | $1,000,215 | $42,900 | 3.9% | |
| Advertising and promotion | $2,522,862 | $51,029 | $2,465,373 | $6,460 | 3.7% | |
| All other expenses | $2,354,543 | $779,441 | $1,484,252 | $90,850 | 3.5% | |
| Occupancy | $2,265,836 | $1,900,357 | $365,479 | - | 3.3% | |
| Other (as described) | EQUIPMENT & SOFTWARE | $2,206,916 | $1,093,771 | $1,113,145 | - | 3.2% |
| Pay: officers, directors, trustees, key employees | $1,616,761 | $327,277 | $1,289,484 | - | 2.4% | |
| Pension plan contributions | $1,560,210 | $944,516 | $590,514 | $25,180 | 2.3% | |
| Payroll taxes | $1,506,770 | $908,912 | $572,678 | $25,180 | 2.2% | |
| Other (as described) | OTHER SCIENTIFIC | $1,202,105 | $1,199,506 | $2,599 | - | 1.8% |
| Travel | $815,559 | $404,647 | $397,383 | $13,529 | 1.2% | |
| Fees: legal | $637,795 | $63,251 | $574,544 | - | 0.9% | |
| Other (as described) | POSTAGE & SHIPPING | $501,746 | $478,540 | $22,622 | $584 | 0.7% |
| Insurance | $425,107 | $263,367 | $161,740 | - | 0.6% | |
| Information technology | $402,742 | $149,624 | $253,038 | $80 | 0.6% | |
| Grants to US individuals | $302,224 | $302,224 | - | - | 0.4% | |
| Pay: disqualified persons | $213,680 | - | $213,680 | - | 0.3% | |
| Conferences, conventions and meetings | $165,374 | $108,462 | $56,912 | - | 0.2% | |
| Fees: accounting | $128,148 | - | $128,148 | - | 0.2% | |
| Office expenses | $112,947 | $60,195 | $52,752 | - | 0.2% | |
| Fees: lobbying | $85,680 | - | $85,680 | - | 0.1% | |
| Total | $68,033,791 | 100% |
2011 · Form 990 · $68,557,809 spent · pay $27,658,068 · grants $341,390 · events $164,918
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $19,866,298 | $10,781,536 | $8,793,980 | $290,782 | 29.0% | |
| Interest | $11,375,530 | $8,869,107 | $2,506,423 | - | 16.6% | |
| Depreciation and depletion | $9,970,658 | $8,061,216 | $1,909,442 | - | 14.5% | |
| All other expenses | $3,787,970 | $1,789,461 | $1,958,799 | $39,710 | 5.5% | |
| Other (as described) | LAB SUPPLIES & SERVICES | $3,248,873 | $3,248,873 | - | - | 4.7% |
| Other employee benefits | $2,549,100 | $1,413,005 | $1,098,522 | $37,573 | 3.7% | |
| Occupancy | $2,448,990 | $1,904,532 | $544,458 | - | 3.6% | |
| Pay: officers, directors, trustees, key employees | $2,248,987 | $1,128,006 | $1,120,981 | - | 3.3% | |
| Fees: other services | $2,245,213 | $1,495,233 | $749,980 | - | 3.3% | |
| Other (as described) | EQUIPMENT & SOFTWARE | $2,033,196 | $1,077,077 | $956,119 | - | 3.0% |
| Pension plan contributions | $1,515,029 | $841,171 | $651,804 | $22,054 | 2.2% | |
| Payroll taxes | $1,478,654 | $818,280 | $638,320 | $22,054 | 2.2% | |
| Other (as described) | OTHER SCIENTIFIC | $1,143,154 | $1,143,154 | - | - | 1.7% |
| Fees: legal | $926,115 | $55,923 | $870,192 | - | 1.4% | |
| Advertising and promotion | $709,562 | $10,046 | $699,516 | - | 1.0% | |
| Travel | $695,945 | $445,065 | $250,880 | - | 1.0% | |
| Other (as described) | SCIENTIFIC PURCH. SVC. | $663,483 | $663,483 | - | - | 1.0% |
| Insurance | $440,991 | $289,362 | $151,629 | - | 0.6% | |
| Information technology | $366,110 | $155,278 | $210,832 | - | 0.5% | |
| Grants to US individuals | $341,390 | $341,390 | - | - | 0.5% | |
| Conferences, conventions and meetings | $164,918 | $91,507 | $73,411 | - | 0.2% | |
| Office expenses | $136,899 | $77,504 | $59,395 | - | 0.2% | |
| Fees: accounting | $132,611 | $15,194 | $117,417 | - | 0.2% | |
| Fees: lobbying | $68,133 | - | $68,133 | - | 0.1% | |
| Total | $68,557,809 | 100% |
2010 · Form 990 · $65,553,404 spent · pay $26,065,382 · grants $340,825 · events $126,927
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $18,030,691 | $9,952,428 | $7,662,767 | $415,496 | 27.5% | |
| Interest | $11,205,203 | $8,647,481 | $2,557,722 | - | 17.1% | |
| Depreciation and depletion | $10,123,630 | $8,209,616 | $1,914,014 | - | 15.4% | |
| Other (as described) | LAB SUPPLIES & SERVICES | $3,464,855 | $3,464,855 | - | - | 5.3% |
| Pay: officers, directors, trustees, key employees | $2,799,911 | $1,527,558 | $1,272,353 | - | 4.3% | |
| Occupancy | $2,570,936 | $1,985,561 | $585,375 | - | 3.9% | |
| Other employee benefits | $2,388,416 | $1,423,583 | $925,003 | $39,830 | 3.6% | |
| Fees: other services | $2,384,795 | $1,805,653 | $579,142 | - | 3.6% | |
| Other (as described) | EQUIPMENT & SOFTWARE | $1,944,232 | $1,106,860 | $837,372 | - | 3.0% |
| All other expenses | $1,859,452 | $543,130 | $1,352,892 | -$36,570 | 2.8% | |
| Pension plan contributions | $1,517,854 | $904,745 | $587,999 | $25,110 | 2.3% | |
| Payroll taxes | $1,328,510 | $791,961 | $514,902 | $21,647 | 2.0% | |
| Fees: legal | $1,133,197 | $69,871 | $1,063,326 | - | 1.7% | |
| Travel | $768,754 | $551,253 | $217,501 | - | 1.2% | |
| Other (as described) | OTHER SCIENTIFIC | $764,424 | $764,424 | - | - | 1.2% |
| Other (as described) | SCIENTIFIC PURCHASED SE | $705,358 | $705,358 | - | - | 1.1% |
| Other (as described) | RECRUITING AND RELOCATI | $586,227 | $227,871 | $358,356 | - | 0.9% |
| Advertising and promotion | $452,400 | $36,261 | $416,139 | - | 0.7% | |
| Insurance | $370,573 | $239,644 | $130,929 | - | 0.6% | |
| Grants to US individuals | $340,825 | $340,825 | - | - | 0.5% | |
| Information technology | $317,986 | $134,979 | $183,007 | - | 0.5% | |
| Fees: accounting | $176,968 | - | $176,968 | - | 0.3% | |
| Office expenses | $141,280 | $82,483 | $58,797 | - | 0.2% | |
| Conferences, conventions and meetings | $126,927 | $94,418 | $32,509 | - | 0.2% | |
| Fees: lobbying | $50,000 | - | $50,000 | - | 0.1% | |
| Total | $65,553,404 | 100% |
2009 · Form 990 · $92,506,520 spent · pay $22,508,665 · grants $221,029 · events $127,649
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other (as described) | TGEN CONTRIBUTION PAYAB | $29,228,120 | $29,228,120 | - | - | 31.6% |
| Other salaries and wages | $14,603,433 | $8,675,344 | $5,673,361 | $254,728 | 15.8% | |
| Interest | $13,165,289 | $10,509,819 | $2,655,470 | - | 14.2% | |
| Depreciation and depletion | $8,753,752 | $7,318,541 | $1,435,211 | - | 9.5% | |
| Pay: officers, directors, trustees, key employees | $3,622,793 | $1,329,366 | $2,293,427 | - | 3.9% | |
| Other (as described) | Lab Supplies & Services | $3,117,006 | $3,101,120 | $15,886 | - | 3.4% |
| All other expenses | $3,060,830 | $1,796,388 | $1,170,343 | $94,099 | 3.3% | |
| Occupancy | $2,521,237 | $2,044,462 | $476,775 | - | 2.7% | |
| Fees: other services | $2,207,131 | $1,372,375 | $834,756 | - | 2.4% | |
| Other employee benefits | $2,049,319 | $1,258,578 | $762,372 | $28,369 | 2.2% | |
| Other (as described) | EQUIPMENT & SOFTWARE | $1,703,707 | $997,274 | $706,433 | - | 1.8% |
| Other (as described) | TGEN INTEGRATION | $1,245,773 | $1,245,773 | - | - | 1.3% |
| Payroll taxes | $1,140,093 | $700,361 | $423,774 | $15,958 | 1.2% | |
| Pension plan contributions | $1,093,027 | $670,914 | $407,337 | $14,776 | 1.2% | |
| Fees: legal | $1,050,515 | $66,018 | $984,497 | - | 1.1% | |
| Other (as described) | MSU DISCOUNT ON PAYABLE | $1,000,746 | $1,000,746 | - | - | 1.1% |
| Travel | $756,248 | $594,240 | $162,008 | - | 0.8% | |
| Advertising and promotion | $619,288 | $59,022 | $560,266 | - | 0.7% | |
| Information technology | $408,781 | $155,053 | $253,728 | - | 0.4% | |
| Insurance | $400,688 | $188,774 | $211,914 | - | 0.4% | |
| Grants to US organizations and governments | $221,029 | $221,029 | - | - | 0.2% | |
| Fees: accounting | $150,165 | - | $150,165 | - | 0.2% | |
| Office expenses | $147,402 | $76,802 | $70,600 | - | 0.2% | |
| Conferences, conventions and meetings | $127,649 | $92,028 | $35,621 | - | 0.1% | |
| Fees: lobbying | $112,499 | - | $112,499 | - | 0.1% | |
| Total | $92,506,520 | 100% |
Comments